

1 **Yellow adipocytes comprise a new adipocyte sub-type present in human bone marrow**

2

3 Camille Attané<sup>1#</sup>, David Estève<sup>1#</sup>, Karima Chaoui<sup>1</sup>, Jason Iacovoni<sup>2</sup>, Jill Corre<sup>3</sup>, Mohamed Moutahir<sup>1</sup>, Philippe  
4 Valet<sup>4</sup>, Odile Schiltz<sup>1</sup>, Nicolas Reina<sup>5,6</sup>, Catherine Muller<sup>1</sup>

5

6 <sup>1</sup> Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse,  
7 France

8 <sup>2</sup> Plateau de Bioinformatiques, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de  
9 Toulouse, INSERM, UPS, Toulouse France

10 <sup>3</sup> Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM, UPS, Toulouse,  
11 France

12 <sup>4</sup> Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, INSERM, UPS,  
13 Toulouse, France

14 <sup>5</sup> Département de Chirurgie Orthopédique et Traumatologique, Hôpital Pierre-Paul Riquet, CHU de Toulouse,  
15 Toulouse, France

16 <sup>6</sup> Laboratoire AMIS, UMR 5288 CNRS, Université Toulouse III-Paul Sabatier, Toulouse, France

17

18 # Contributed equally to this work

19 **Corresponding author(s):** Pr Catherine Muller, IPBS CNRS UMR 5089, 205 route de Narbonne, 31077 Toulouse

20 Tel: 33-561-17-59-32; Fax: 33-561-17-59-33; e-mail: [muller@ipbs.fr](mailto:muller@ipbs.fr)

21

22 **Running title**

23 Defect of lipolysis in bone marrow adipocytes

24

25 **Abstract**

26 During energy demanding conditions, white adipocytes store triglycerides and release fatty acids through lipolysis.  
27 In contrast, bone marrow adipocytes (BM-Ad) increase in size during caloric restriction, suggesting this fat depot  
28 exhibits precise metabolic specificity. We found subcutaneous adipocytes (SC-Ad) and BM-Ad share  
29 morphological features, but possess distinct lipid metabolism. BM-Ad show enrichment in cholesterol-oriented  
30 metabolism that correlates with increased free cholesterol content, while proteins involved in lipolysis were  
31 downregulated. A strong down-regulation in expression of monoacylglycerol (MG) lipase was observed leading  
32 to an accumulation of major MG species and accordingly the basal and induced lipolytic responses were absent in  
33 BM-Ad. These features are not recapitulated *in vitro* using differentiated bone marrow mesenchymal stem cells.  
34 Since our data demonstrate that BM-Ad comprise a distinct class of adipocytes, we propose renaming them yellow  
35 adipocytes.

36

37 **Keywords**

38 Bone Marrow adipocytes / cholesterol/lipolysis / monoacylglycerol lipase / proteomic

## 1 **Introduction**

2 In mammals, white adipose tissue (WAT) accumulates at various sites throughout the body. The most important  
3 and well-studied fat deposits occur in subcutaneous regions (SC-AT) and in the abdominal cavity surrounding key  
4 internal organs like the pancreas and intestines (Zwick et al, 2018). Other adipose-specific deposits also form  
5 around the heart, kidney, prostate in men and mammary glands in women (Zwick et al, 2018). In addition to WAT,  
6 mammals also possess brown adipose tissue (BAT) located in the interscapular and supraclavicular regions,  
7 representing less than 5% of the total fat mass (Leitner et al, 2017; Nedergaard et al, 2007; Saito et al, 2009;  
8 Zingaretti et al, 2009). Brown adipocytes participate in non-shivering thermogenesis and possess a specific  
9 morphology that includes several small lipid droplets and high mitochondria content (Bartelt & Heeren, 2014;  
10 Cinti, 2001). In contrast, white adipocytes store energy as triglycerides (TG) in their unique large lipid droplet  
11 (LD) after energy intake and release free fatty acids (FFA) through lipolysis in energy demanding conditions  
12 (Zechner, 2015). Lipolysis occurs through a biochemical pathway that uses consecutive actions of adipose  
13 triglyceride lipase (ATGL), which catalyzes the conversion of TG to diacylglycerols (DG) and hormone-sensitive  
14 lipase (HSL) and hydrolyzes DAG to monoacylglycerols (MG), monoacylglycerol lipase (MAGL) and the newly  
15 identified  $\alpha/\beta$  hydrolase domain-containing protein 6 (ABHD6), which hydrolyzes MG to FA (Zhao et al, 2016)  
16 and glycerol (Zechner, 2015). White adipocytes also have an important endocrine function as they can release  
17 multiple soluble factors called adipokines, such as leptin and adiponectin (Fasshauer & Blüher, 2015).

18 One intriguing adipose tissue (AT) localizes to the bone marrow called bone marrow adipose tissue (BM-AT) that  
19 constitutes over 10% of the total fat mass in lean and healthy humans (Cawthorn et al, 2014). Technological  
20 advances in quantitative imaging of BM-AT in both mice and humans revealed that BM-AT presents unique  
21 features that highlight their physiological specificity. Many studies demonstrated that BM-AT increases in  
22 different pathophysiological conditions such as aging (Justesen et al, 2001; Scheller et al, 2015), osteoporosis  
23 (Justesen et al, 2001; Yeung et al, 2005) and obesity (Bredella et al, 2010; Doucette et al, 2015). These findings  
24 suggest this adipocyte population plays a larger role beyond that of “filler-cells”. In stark contrast to the other  
25 WAT, the number and size of bone marrow adipocytes (BM-Ad) also increase during caloric restriction conditions  
26 in mice (Cawthorn et al, 2014; Devlin et al, 2010), rabbits (Bathija et al, 1979; Tavassoli, 1974) and human patients  
27 suffering from anorexia nervosa (Abella et al, 2002; Bredella et al, 2010). Decreases in bone marrow adiposity  
28 occurs only in severe nutrient deprivation in rabbits (Cawthorn et al, 2016) and late stages of anorexia nervosa  
29 associated with gelatinous transformation of the bone marrow (BM) [(Abella et al, 2002); for review (Ghali et al,  
30 2016)].

31 Given the significant role for AT in regulating energy homeostasis, it is critical to elucidate why this tissue copes  
32 with changes in energy status in such a specific way that leads to still store and not dispense fuel when needed.  
33 However, knowledge of the phenotype of primary BM-Ad in physiology is sparse and hampered by difficulty to  
34 obtain sufficient isolated BM-Ad in mice and from harvesting human BM-AT partly due to the physical location  
35 (inside bone). Most studies on BM-Ad use rodents or human *in vitro* models. Mouse studies indicate BM-Ad  
36 regulate hematopoiesis and bone mass (Naveiras et al, 2009; Zhou et al, 2017). However, species-specific  
37 differences between rodent and human BM-AT exist that reinforce using caution when extrapolating information  
38 across species (Scheller et al, 2016). Two types of adipocytes in mouse have been described: regulatory and  
39 constitutive BM-Ad (rBM-Ad and cBM-Ad, respectively) (Scheller et al, 2015). cBM-Ad are present in tail  
40 vertebrae and the medullary canal from the tibia-fibular junction into the malleolus. However, rBM-Ad develop

1 postnatally within the BM of long bones extending from below the growth plate through the metaphysis and into  
2 the diaphysis (Scheller & Rosen, 2014). Existence of these two populations remains unconfirmed in humans. Inside  
3 the diaphysis of long bone, the number of BM-Ad varies between mouse strains and species, and some strains  
4 require pharmacological induction of BM-Ad by drugs such as glucocorticoids and thiazolidinedione (Scheller et  
5 al, 2016). Yet, human BM-Ad consistently fill 50 to 70% of the bone marrow cavity (Hindorf et al, 2010). Many  
6 studies use bone marrow mesenchymal stromal cells (BM-MSC) differentiated in adipocytes *in vitro*. However, it  
7 is unclear whether these differentiated cells recapitulate the phenotype of mature human primary BM-Ad. These  
8 *in vitro* studies suggest a role for BM-Ad in hematopoiesis regulation (Mattiucci et al, 2018; Naveiras et al, 2009),  
9 bone remodeling (Hardaway et al, 2015) and cancer progression (Diedrich et al, 2016; Herroon et al, 2013; Liu et  
10 al, 2015; Shafat et al, 2017; Tabe et al, 2017). These issues highlight that our knowledge of the physiological  
11 phenotype of primary BM-Ad remains limited. Using combined lipidomic and proteomic large-scale approaches,  
12 we purified and characterized human BM-Ad harvested from the femoral diaphysis of patients undergoing hip  
13 surgery with paired subcutaneous adipocytes (SC-Ad) and found that BM-Ad exhibit clearly distinct lipid  
14 metabolic features that reveal a new adipocyte sub-type.

15

16

## 1 **Results/Discussion**

### 2 **Isolated SC-Ad and BM-Ad share morphological properties of white adipocytes.**

3 After harvesting paired SC-AT and BM-AT from patients undergoing hip replacement surgery, we isolated  
4 adipocytes after collagenase digestion (Fig 1A). In AT from both locations, the vast majority of the space contained  
5 large and cohesive mature adipocytes with a unique LD filled with neutral lipids (assessed by Bodipy staining)  
6 (Fig 1B). Mature adipocytes from both locations expressed perilipin 1 (PLIN1) at the surface of the LD (Fig EV1A-  
7 B) and exhibited a very thin cytoplasm rim, a morphological trait expressed by white adipocyte (Fig EV1B) (Cinti,  
8 2001). SC-AT and BM-AT also contained blood vessels highly positive for actin staining and stroma vascular cells  
9 at both stromal and perivascular positions (Fig 1B and Fig EV1A). Using transmission electron microscopy  
10 approach, we observed that both SC-Ad and BM-Ad present in the AT display a large LD surrounded by a very  
11 thin cytoplasm with the nucleus located at the cell periphery between the plasma membrane and the LD (Fig 1C).  
12 We performed an enzymatically based digestion protocol to isolate adipocytes from both tissues. After obtaining  
13 a population of cells constituted only of adipocytes, our results indicated that our tissue dissociation preserved the  
14 morphological identity of the isolated adipocytes. The isolated BM-Ad and SC-Ad shared the same morphology  
15 found within the tissues characterized by the presence of a unique and large LD filled with neutral lipids (Fig 1D).  
16 In addition, F-Actin staining showed a similar cytoskeleton architecture between the two types of cells (Fig 1D).  
17 Taken together, our results demonstrate the BM-AT present in the diaphysis of long bone is composed of cohesive  
18 adipocytes that exhibit the morphological appearance of white adipocytes as assessed by their unique LD,  
19 surrounded by a thin cytoplasm and a nucleus present at the periphery of the cells. With the caution noted in the  
20 introduction, a recent study in mice that used electronic transmission found that BM-Ad exhibit similar rounded  
21 morphology with a unique large LD (Robles et al, 2019). Yet, a recent report suggested that mouse BM-Ad express  
22 some genes related to BAT, including PRDM16 and FOXC2 (Krings et al, 2012). However, this study used whole  
23 tibia extracts, which contain adipocytes and contaminating cells, including myeloid cells and osteoblasts that  
24 express PRDM16 and FOXC2, respectively (Kim et al, 2009; Nishikata et al, 2011). Here, we present an initial  
25 morphological characterization of human BM-Ad, where they exhibit traits of white adipocytes that do not clearly  
26 distinguish them from “classical” white adipocytes.

### 27 **Lipid profile in BM-Ad reveals enriched diverse lipid species like monoacylglycerol (MG) and cholesterol.**

28 We then further characterized the phenotype of BM-Ad by studying their lipid profile compared to SC-Ad. Lipids  
29 were extracted from tissues and isolated adipocytes. As shown in Fig 2A, each tissue and isolated adipocytes  
30 showed a similar total lipid content. A quantitative LC-MS/MS based analysis of the total lipid content extracted  
31 from BM-Ad and SC-Ad was performed using a recently developed approach that uses both positive and negative  
32 ionization modes to cover the largest spectrum of detectable lipid species (Breitkopf et al, 2017). The analysis  
33 structurally characterized and identified 818 lipid species originating from the main lipid categories that belonging  
34 to 15 lipid classes. The majority of identified lipid species were glycerolipids (GL), including triacylglycerol (TG,  
35 95 %) and diacylglycerol (DG, 2.1%). Beyond GL, the remaining lipids contain a large spectrum of phospholipids  
36 (PL), in particular phosphatidylcholine (PC, 1.9%), a major membrane constituent (Wen et al, 2018), sphingolipids  
37 (SL) and fatty esters (Fig 2B).

38 Unsupervised multivariate analyses of our lipidomic dataset indicated the variance between samples  
39 predominantly arose through inter-individual variability (Fig EV2A-B) indicating the lipids stored within mature

1 adipocytes likely came from food intake. We conclude that BM-Ad lipid composition reflects dietary lipid intake,  
2 which is consistent with a prior report in SC-Ad (Hodson et al, 2008). We then investigated if differences exist in  
3 lipid classes between SC-Ad and BM-Ad by comparing all quantified lipid species for one class between the two  
4 locations. As shown in Fig 2C, we observed differences in GL content. BM-Ad, in all samples, exhibited a slight  
5 increase in TG content with no changes in DG levels. MG content increased (Fig 2C), which reflected an increase  
6 of both saturated and unsaturated major MG species (Fig EV2C). These results suggest that the hydrolysis of MG  
7 is not efficient in BM-Ad. Two additional lipid classes are also increased in BM-Ad compared to SC-Ad, wax  
8 esters and sphingosine. Of note, only three sphingosine species were detected. The LC-MS/MS approach we used  
9 to quantify the lipid species does not identify cholesterol species, a key lipid species contained in adipocyte LD  
10 (Schreibman & Dell, 1975). Using a colorimetric assay, we found that BM-Ad showed a 1.5-fold increase in free  
11 cholesterol content compared to SC-Ad (Fig 2D). Cholesterol ester was not detected in either sample as we  
12 predicted since the vast majority of cholesterol is expressed in a free form in adipocytes (Schreibman & Dell,  
13 1975). Here, we characterize the lipid content in BM-Ad using unsupervised lipidomic approaches. Inter-  
14 individual variability suggests that BM-Ad lipid content partially reflects dietary intake as in other adipose depots.  
15 Our results demonstrate that intrinsic differences exist between BM-Ad and SC-Ad regarding free cholesterol and  
16 MG contents.

17

### 18 **Proteome of BM-Ad and SC-Ad differentiates adipocytes in lipid metabolic functions**

19 We sought to further decipher the metabolic pathways specifically present in BM-Ad, so we conducted a large-  
20 scale proteomic analysis on paired SC-Ad and BM-Ad. We detail the data analysis general strategy in Fig EV3A.  
21 After data quality control, 3259 proteins were robustly detected. Interestingly, when we searched for proteins  
22 known to be secreted by adipocytes, termed adipokines (Fasshauer & Blüher, 2015), our dataset did not highlight  
23 significant differences between the two types of adipocytes and K-means clustering based on the expression  
24 pattern of adipokines did not allow clustering of the samples according to their anatomical location (Fig EV3B).  
25 BM-Ad expressed the adipocyte-specific adipokine, adiponectin, at the same levels as SC-Ad (Fasshauer &  
26 Blüher, 2015) (ADIPOQ, Table EV1). We obtained similar results for leptin (LEP, Table EV1), a hormone  
27 predominantly produced by adipocytes (Fasshauer & Blüher, 2015). These results indirectly assess the quality of  
28 cell preparation and their purity.

29 Among the 3259 proteins detected, 612 proteins involved in glucose and lipid metabolism were identified. We  
30 performed an unsupervised multivariate analysis focused on these proteins, which clearly demarcated the 4  
31 samples according to their anatomical location (Fig 3A). The first two components of this analysis explained 41%  
32 and 20.8% of the dataset variance, respectively (Fig 3A). Statistical analysis of the 612 metabolic proteins  
33 differentially expressed in BM-Ad compared to SC-Ad identified 68 up-regulated proteins and 67 down-regulated  
34 proteins (Fig 3B). Pathway enrichment analysis with gene analytic software showed clear differences in the  
35 expression of proteins involved in several lipid metabolism pathways according to their anatomical locations (Fig  
36 3C). Compared to SC-Ad, BM-Ad showed enrichment in arachidonic acid (AA) metabolism, SL signaling  
37 pathway and cholesterol metabolism delineated through cholesterol biosynthesis and statin pathways, while BM-  
38 Ad displayed downregulation of glucose and FA metabolism, as well as lipolysis regulation pathways (Fig 3C).  
39 Lipoprotein metabolism was also enriched and down-regulated in BM-Ad compared to SC-Ad (Fig 3C). In depth  
40 analysis of the proteins differentially expressed in this pathway revealed unexpected specificity for each fat depot.

1 We uncovered a clear separation of the samples by their location using hierarchical clustering dendrogram (Fig  
2 3D). In BM-Ad, proteins involved in cholesterol transport (apolipoproteins APO-A2, -C1 and -C4) and  
3 hydrolysis, such NCEH1 (Neutral Cholesterol Ester Hydrolysis) and LIPA (Lipase A) (Litvinov et al, 2018), were  
4 enriched. This cholesterol-oriented metabolism in BM-Ad is strengthening by the enrichment of several proteins  
5 involved in cholesterol biosynthesis and statin pathways (Fig EV3C). On the opposite, proteins related to lipolysis  
6 were down-regulated in BM-Ad compared to SC-Ad in lipoprotein metabolism pathway (Fig 3D). Surprisingly,  
7 the lipases involved in TG hydrolysis LIPE (gene name of HSL) and MGLL (gene name of MAGL) were decreased  
8 ( $1.19 \pm 0.80$ ,  $p = 0.016$  for LIPE and  $-2.45 \pm 0.35$   $p = 0.00024$  for MGLL, see Table EV1), as well as the Fatty  
9 Acid Binding Protein 4 (FABP4), one of the most abundant proteins in adipocytes that participate in maintaining  
10 adipocyte homeostasis and regulating lipolysis and adipogenesis (Prentice et al, 2019). Finally, BM-Ad and SC-  
11 Ad exhibited distinct expression patterns of proteins involved AA metabolism and FA metabolism (Fig EV3D-E).  
12 Despite similar morphology and expression pattern of adipokines, our results strongly support that BM-Ad are  
13 adipocytes that exhibit a very specific lipid metabolism compared to the “classical” SC-Ad. We uncovered an  
14 accumulation of free cholesterol in these cells. This conclusion is supported by unbiased proteomic approaches  
15 that indicate a seemingly unidentified cholesterol-oriented metabolism. In contrast to our results, a recent  
16 transcriptomic study comparing gene expression of human BM-Ad isolated from the femoral head and SC-Ad  
17 show that genes over-represented in human BM-Ad participate in signaling pathways without clear differences in  
18 the enzymes involved in lipid metabolism (such as cholesterol metabolism and TG hydrolysis) (Mattiucci et al,  
19 2018). In addition, this report found decreased adiponectin expression, which stand in contrast to our current results  
20 and another study that identified BM-Ad as an important source of adiponectin (Cawthorn et al, 2014). We  
21 speculate technical issues, such as transcriptomic vs proteomic, and the different sources of BM-Ad used may  
22 underlie the differences in these findings. We suspect that the specificity of BM-Ad in cholesterol metabolism may  
23 reflect their role in supporting BM hematopoiesis (Naveiras et al, 2009; Zhou et al, 2017). Cholesterol is essential  
24 constituent of the plasma membrane (Abe & Kobayashi, 2017) and could sustain cell division and plasma  
25 membrane fluidity and synthesis of surrounding hematopoietic cells that are under constant renewal. In contrast,  
26 the main functions of adipocytes, liberating energy reserve stores as TG under times of energy demand, appears  
27 downregulated in these cells. This interesting observation is consistent with the absence of a decrease in BM  
28 adiposity under energy deficit conditions (Bathija et al, 1979; Cawthorn et al, 2014; Devlin et al, 2010; Tavassoli,  
29 1974). In particular, we observed a critical down-regulation of MAGL expression, a lipase required for the final  
30 hydrolysis of MG produced by HSL activation (Zechner, 2015). As such, MAGL deficiency in mice leads to a  
31 concomitant increase in MG levels in AT (Taschler et al, 2011) as observed in BM-Ad. The concomitant decrease  
32 of MAGL expression and increase in MG species strongly suggests that MAGL activity may be impaired in BM-  
33 Ad compared to SC-Ad.

34

### 35 **Human primary BM-Ad present a defect in lipolytic activity not recapitulated in *in vitro* models**

36 Due to the potential high impact of this newly described regulation in BM-Ad physiology, we further characterized  
37 the lipolytic pathway using Western blot analysis of the three major lipases involved in the consecutive hydrolysis  
38 of TG. While we observed no differences in ATGL and HSL expression in BM-Ad compared to paired SC-Ad,  
39 we found a sharp decrease (about 5-fold) in MAGL (Fig 4A). While we found a slight (1.21-fold) decrease in HSL  
40 protein expression in our proteomic studies, this result was not reproduced using Western blot analysis. This



1 discrepancy highlights inter-individual variability. We then functionally assayed lipolytic activity using *ex vivo*  
2 approaches on isolated adipocytes. Under basal conditions, we observed reduced glycerol and FFA release in BM-  
3 Ad compared to SC-Ad (Fig 4B and 4C). Under isoprenaline stimulation (a  $\beta$ -adrenergic agonist that serves as a  
4 strong lipolytic inductor) (Lafontan & Langin, 2009), we found no increase in glycerol (reflecting complete  
5 lipolytic reactions) or significant FFA release, but we did find a 3-fold increase in SC-Ad as expected (Lafontan  
6 & Langin, 2009). Thus, our data clearly demonstrate that human BM-Ad are devoid of lipolytic activity, which  
7 confirms their metabolic specificity.

8 A key finding from our study is the profound down-regulation of MAGL expression, which has never been  
9 reported for other AT. Strikingly, the two lipases ATGL and HSL possess several regulators of their activity  
10 involving interaction with other proteins as well as phosphorylation state under the control of hormones such as  
11 catecholamines (Lafontan & Langin, 2009). However, there is no evidence that cell energy status or hormones can  
12 influence MAGL activity, which renders it constitutively active (Lafontan & Langin, 2009). Since BM-Ad down-  
13 regulate MAGL expression, this indicates that these cells use the only efficient way to inhibit this specific activity.  
14 The slight, but not significant, increase of FFA upon lipolytic stimulation in BM-Ad (Fig 4C) suggests that the  
15 lipolysis process is not completely effective in these cells. In mice, a study suggests that rat cBM-Ad (from tail  
16 vertebrae) and rBM-Ad (from proximal tibia and femur) are resistant to lipolysis induced by  $\beta$ -adrenergic stimuli.  
17 This corresponds at the molecular level to a decrease in active phosphorylation of HSL, whereas the levels of  
18 ATGL and HSL remained unchanged compared to SC-Ad (Scheller et al, 2019). Such an additional regulatory  
19 process could also occur in human BM-Ad. Interestingly, the MAGL defect in BM-Ad is not compensated by  
20 ABHD6 expression, another lipase known to hydrolyze MG in visceral and brown AT but not in SC-AT (Zhao et  
21 al, 2016). ABHD6 expression levels remained constant between BM-Ad and SC-Ad in our proteomic study (Table  
22 EV1).

23 We then focused on the metabolic characteristic of BM-Ad we discovered, so we examined the physiological  
24 relevance of *in vitro* differentiated adipocytes used as the gold standard model for studying the role of BM-Ad.  
25 We differentiated human primary BM-MSCs and murine BM-MSC OP9 cell lines *in vitro* under adipogenic  
26 conditions. The murine pre-adipocyte 3T3-F442A served as a control reflecting “classical adipocytes”. In all cells,  
27 the differentiation process strongly increased TG content (Fig 4D). *In vitro* differentiated adipocytes from BM-  
28 MSCs exhibited similar levels of basal lipolysis compared to differentiated 3T3-F442A (Fig 4E). Isoprenaline  
29 stimulation increased glycerol release in all cells studied (Fig 4E). These experiments demonstrated that adipocytes  
30 obtained from *in vitro* differentiation of human BM-MSCs do not recapitulate the functional defect in lipolysis  
31 observed in BM-Ad isolated from patients. We conclude from these results that *in vitro* differentiated BM-MSCs,  
32 considered the gold standard for studying BM-Ad functions, should be interpreted with high caution, since these  
33 cells do not recapitulate of key metabolic trait of the BM-Ad phenotype. The differentiation program of BM-Ad  
34 may exhibit distinct developmental gene expression patterns and epigenetic signatures that are not induced by the  
35 most widely used differentiation protocols that add PPAR $\gamma$  agonists (Lee & Fried, 2014; Ninomiya et al, 2010;  
36 Scott et al, 2011). We suggest that such protocols may artificially force BM-Ad progenitors towards a  
37 differentiation program into classical white adipocytes.

38  
39  
40

## 1 **Conclusion**

2 Here, we pioneered a methodology to characterize human primary BM-Ad using combined large-scale proteomic  
3 and lipodomic approaches. This approach revealed specific markers in a phenotype that refines and identifies BM-  
4 Ad. These cells morphologically resemble classical SC-Ad; however, we unraveled the specific lipid metabolism  
5 of BM-Ad, including the presence of a cholesterol-orientated metabolism that requires further investigation. We  
6 demonstrated altered lipolytic function in human primary BM-Ad due to a profound down-regulation of MAGL  
7 expression. This result underlies the differences in metabolic fitness upon caloric restriction between BM-AT and  
8 SC-AT. This specific phenotype is a previously unidentified feature of adipose depots that could explain why BM-  
9 AT behaves like a preserved lipid source, except during periods of extremely severe nutrient deprivation (Abella  
10 et al, 2002; Cawthorn et al, 2016). The specific function of this preservation, whether overall metabolic fitness or  
11 local interaction with proximal cells (such as hematopoietic cells), remains unknown. Adipocyte diversity  
12 continues to increase, so distinguishing markers and delineating specific phenotypes of these adipocyte subtypes  
13 gain importance. In addition to white and brown adipocytes, recent studies have identified beige adipocytes, an  
14 inducible form of thermogenic adipocytes (Zwick et al, 2018) and pink adipocytes in mouse mammary fat pad  
15 during pregnancy and lactation (Giordano et al, 2014). Given their specificity for lipid metabolism regardless of  
16 their morphological similarity to white adipocytes, we propose to define BM-Ad as a distinct type of adipocytes  
17 named “yellow adipocytes”.

18

19

20



## 1 **Materials and Methods**

### 2 **Human subcutaneous and bone marrow tissue samples.**

3 Paired subcutaneous (SC-AT) and bone marrow adipose tissue (BM-AT) were harvested from patients undergoing  
4 hip surgery in the Orthopedic Surgery and Traumatology Department of the Hospital Pierre Paul Riquet (Toulouse,  
5 France). All patients gave their informed consent and the samples were obtained according to national ethic  
6 committee rules (authorization° DC-215-2342). Briefly, during total hip replacement surgeries, after skin incision,  
7 maximus gluteus muscle and external rotators dissection, an osteotomy of the femoral neck was performed which  
8 allowed access to the intramedullary canal. While broaching the canal, BM-AT was aspirated cautiously with a  
9 soft cannula in the femoral proximal metaphysis and diaphysis before prosthesis placement. All procedures were  
10 performed using the same posterior approach. SC-AT were harvested using surgical blade at the incision site in  
11 the gluteal region. The samples were immediately placed in 37°C pre-warmed KRBHA (Krebs Ringer BSA  
12 HEPES Albumin buffer) corresponding to Krebs Ringer buffer (Sigma-Aldrich) supplemented with 100mM Hepes  
13 (Sigma-Aldrich) and 0.5% free fatty acid (FFA-free) bovine serum albumin (BSA) (Sigma-Aldrich) and rapidly  
14 carried out to the laboratory (within 1h) where they were processed. The BM-AT that share the same macroscopic  
15 aspects compared to SC-AT was dissected from area rich in hematopoietic cells (red marrow). For all the  
16 experiments performed in our study, 24 independent samples were used and obtained from 14 men and 10 women  
17 (mean age:  $66.7 \pm 13.9$  years and mean body mass index (BMI):  $26.8 \pm 3.4$  kg/m<sup>2</sup>).

18

### 19 **Adipocyte isolation.**

20 SC-AT and BM-AT were rinsed several times in KRBHA prior to collagenase digestion (250 UI / mL diluted in  
21 PBS calcium and magnesium free supplemented with 2% FFA-free BSA (all products were obtained Sigma-  
22 Aldrich). After 30 min digestion at 37°C under constant shaking, samples were filtered with 100 and 200µm cell  
23 strainers (for BM-AT and SC-AT respectively) to remove cellular debris, undigested fragments and bone  
24 trabeculae. The cell suspension was then gently centrifuged for 5 min at 200g at room temperature (RT). The  
25 floating adipocytes were then collected and rinsed with KRBHA several times to obtain a pure adipocyte cell  
26 suspension.

27

### 28 **SC-AT and BM-AT confocal microscopy**

29 Pieces of 0.5 cm<sup>2</sup> of whole SC-AT and BM-AT were fixed with a 4% paraformaldehyde solution (PFA, Electron  
30 Microscopy Sciences (EMS)) overnight. Fixed tissues were blocked and permeabilized in calcium and magnesium  
31 free PBS supplemented with 3% BSA and 0.2% Triton X100 (both obtained from Sigma Aldrich) for 1 h at RT.  
32 Tissues were then incubated overnight with a mouse anti PLIN1 serum (Acris Biosystem; 1:10 in calcium and  
33 magnesium free-PBS, 3% BSA, 0.2% Triton X-100). The following day the tissues were rinsed 5 times in PBS  
34 0.05% Tween-20 and incubated for 2 h with a secondary antibody coupled with CF488 dye (Biotum) for PLIN1  
35 staining, rhodamine coupled phalloidin (Thermofisher) for filamentous actin staining and TOPRO3®  
36 (Thermofisher) for nuclei staining. Z-stack images were acquired using LSM 710 confocal microscope and a 10X  
37 or 40X objective (Zeiss). Maximum intensity projection was made using Image J software and orthogonal views  
38 using Imaris software (v9.2; Bitplane).

39

## 1 **Transmission electron microscopy**

2 SC-AT and BM-AT were fixed with 2,5% glutaraldehyde and 2% PFA (EMS, Hatfield, PA, USA) in Cacodylate  
3 buffer (0.1M, pH 7.2) overnight at 4 °C and post-fixed at 4°C with 1% OsO<sub>4</sub> and 1.5% K<sub>3</sub>Fe(CN)<sub>6</sub> in the same  
4 buffer. Samples were treated for 1 h with 1% aqueous uranyl acetate and were then dehydrated in a graded ethanol  
5 series and embedded in EMBed-812 resin (EMS). After 48 h of polymerization at 60 °C, ultrathin sections (80 nm  
6 thick) were mounted on 75 mesh formvar-carbon coated copper grids. Sections were stained with 2% uranyl acetate  
7 (EMS) and 3% Reynolds lead citrate (Chromalys). Grids were examined with a TEM (Jeol JEM-1400, JEOL Inc)  
8 at 80 kV. Images were acquired using a digital camera (Gatan Orius, Gatan Inc, Pleasanton, CA, USA).

9

## 10 **Confocal microscopy on isolated adipocytes**

11 BM-Ad and SC-Ad were isolated as described above. Immediately after isolation, primary adipocytes were  
12 embedded in a fibrin gel to maintain cellular integrity. Briefly, 30µl of isolated adipocytes were gently mixed with  
13 30µl of a fibrinogen solution (18 µg/mL in 0.9% NaCl buffer, Sigma-Aldrich) and 30µl of thrombin (3 units in  
14 30µl of CaCl<sub>2</sub> solution, Sigma-Aldrich). Gel polymerization occurs rapidly at 37°C. The gels containing the  
15 primary adipocytes were fixed in 4% PFA for 1h and incubated with 10 ng/mL of Bodipy<sup>®</sup> 493/503, rhodamine  
16 coupled phalloidin and TOPRO3 (all products were obtained from Thermofischer). Samples were examined using  
17 LSM 710 confocal microscope and a 40X objective (Zeiss). Maximum intensity projection was performed using  
18 Image J software.

19

## 20 **Lipidomic analysis**

21 For the lipidomic and proteomic studies, 4 samples were used (2 men and 2 women, mean age: 67± 7. 4 years;  
22 mean BMI: 26.5 ± 3.1 kg/m<sup>2</sup>). After 3 washes with PBS, isolated adipocytes (400 µl) were mixed 1.5 mL methanol  
23 in glass tubes. Sample mixture was then incubated with 5 mL of methyl tert-butyl ether (MTBE ;Sigma-Aldrich)  
24 for 1h at RT under gently shaking. After adding 1.2 mL of water, samples were centrifuged for 10 min at 1000 g.  
25 Upper phase (containing lipids) was transferred in a new glass tube. Lower phase was re-extracted with 2 volume  
26 parts of MTBE: methanol: water (10: 3: 2.5) and samples were centrifuged for 10 min at 1000 g and used for  
27 proteomic analyses (see below). Upper phase was collected, combined with the one collected after the first  
28 extraction and kept at -80°C for lipidomic analysis. One ml of lipid phase was evaporated under a nitrogen stream.  
29 Dried samples were sent to the Harvard mass spectrometry core and were analyzed by their untargeted lipidomics  
30 profiling platform. Lipids were resuspended with 100µl of 1:1 LC/MS grade isopropanol: acetonitrile methanol  
31 and 5 µl were injected onto the LC-MS/MS. Data acquisition was performed as previously described (Breitkopf  
32 et al, 2017). Briefly, each peaks area was calculated in both positive and negative ionization mode. The peaks  
33 allowing to structurally resolving the same lipid species were sum, if obtained from the same ionization. Only the  
34 lipid species detected at least in 3 samples from the same location were considered as robustly detected and used  
35 for the analysis. Missing values were imputed as the first percentile of the entire dataset. Then, values were log<sub>2</sub>  
36 transformed and normalized with the function NormalizeBetweenArrays from Bioconductor package to perform  
37 the principal component analysis with R software (v3.5) and FactomineR package. The heatmaps and associated  
38 hierarchical clustering build on K-means methods were resolved with R software and ggplot2 package after  
39 centering the data around zero. The lipid species belonging to the same classes were sum to measure their relative

1 abundance and the log<sub>2</sub> fold change of signal intensities for each class was calculated to compare the lipid classes  
2 between adipocyte locations. Violin plot was drawn with vioplot function in R.

3

#### 4 **Cholesterol content quantification**

5 Cholesterol content within isolated adipocytes was measured using cholesterol assay kit (obtained from Abcam-  
6 ab65390) according to manufacturer recommendations. Briefly, lipids were extracted from isolated adipocytes  
7 using MTBE as described above. Free cholesterol and total cholesterol was sequentially quantified using  
8 colorimetric method. Optical density was determined at 570 nm with  $\mu$ -quant spectrophotometer (BioTek  
9 Instruments).

10

#### 11 **Proteomic analysis**

12 After 3 washes with PBS, proteins from isolated adipocytes (400 $\mu$ l) were purified with 5 mL of MTBE as described  
13 in lipidomic analysis section. Lower phase was centrifuged for 10 min at 5000 g at RT and pellet (containing  
14 proteins) was washed 2 times with PBS to remove solvents. Pellets were then resuspended with PBS 2% SDS,  
15 sonicated for 20 seconds and protein concentration was determined with the commercial kit (DC<sup>TM</sup> Protein Assay;  
16 Bio-Rad). Fifteen  $\mu$ g of proteins were reduced with modified Laemmli buffer (40 mM Tris pH 6.8, 2% SDS, 10%  
17 glycerol, 25mM DTT and 0.01% bromophenol blue) for 15 min at 65°C and alkylated by addition of 90mM  
18 iodoacetamide for 30 min at RT in the dark. Protein samples were loaded on a 1D SDS-PAGE gel (0.15 x 8 cm)  
19 and the electrophoretic migration was stopped as soon as the proteins entered the separating gel, in order to isolate  
20 all proteins in a single gel band (stained with Coomassie blue). The corresponding gel slice was excised and washed  
21 with 100 mM ammonium bicarbonate buffer. Proteins were in-gel digested using 0.6  $\mu$ g of modified sequencing  
22 grade trypsin (Promega) in 50 mM ammonium bicarbonate overnight at 37°C. The resulting peptides were  
23 extracted in 50 mM ammonium bicarbonate followed by 10% formic acid/acetonitrile (1/1 v/v). The peptidic  
24 fractions were dried under speed-vacuum and resuspended with 5% acetonitrile, 0.05% trifluoroacetic acid (TFA)  
25 for MS analysis.

26 Peptides were analyzed by nanoLC-MS/MS using an UltiMate 3000 RSLCnano system coupled to a Q-Exactive  
27 Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Five  $\mu$ L of each sample were loaded on a  
28 C-18 precolumn (300  $\mu$ m ID x 5 mm, Thermo Fisher) in a solvent made of 5% acetonitrile and 0.05% TFA and at  
29 a flow rate of 20  $\mu$ L/min. After 5 min of desalting, the precolumn was switched online with the analytical C-18  
30 column (75  $\mu$ m ID x 15 cm, Reprosil C18) equilibrated in 95% solvent A (5% acetonitrile, 0.2% formic acid) and  
31 5% solvent B (80% acetonitrile, 0.2% formic acid). Peptides were eluted using a 5 to 50% gradient of solvent B  
32 over 300 min at a flow rate of 300 nL/min. The Q-Exactive Plus was operated in a data-dependent acquisition  
33 mode with the XCalibur software. MS survey scans were acquired in the Orbitrap on the 350-1500 m/z range with  
34 the resolution set to a value of 70000. The 10 most intense ions per survey scan were selected for HCD  
35 fragmentation and the resulting fragments were analyzed in the Orbitrap with the resolution set to a value of 17500.  
36 Dynamic exclusion was employed within 30 seconds to prevent repetitive selection of the same peptide. Duplicate  
37 technical LC-MS measurements were performed for each sample.

38 Raw mass spectrometry files were processed with the MaxQuant software (version 1.6.3.4) for database search  
39 with the Andromeda search engine and quantitative analysis. Data were searched against human entries of the  
40 Swissprot protein database (UniProtKB/Swiss-Prot Knowledgebase release 2018\_02). Carbamidomethylation of

1 cysteines was set as a fixed modification whereas oxidation of methionine and protein N-terminal acetylation were  
2 set as variable modifications. Specificity of trypsin digestion was set for cleavage after K or R, and two missed  
3 trypsin cleavage sites were allowed. The precursor mass tolerance was set to 20 ppm for the first search and 4.5ppm  
4 for the main Andromeda database search. The mass tolerances MS/MS mode was set to 0.5 Da. Minimum peptide  
5 length was set to seven amino acids, and minimum number of unique peptides was set to one. Andromeda results  
6 were validated by the target-decoy approach using a reverse database at both a peptide and a protein FDR of 1%.  
7 For label-free relative quantification of the samples, the “match between runs” option of MaxQuant was enabled  
8 with a time window of 0.7min, to allow cross-assignment of MS features detected in the different runs.  
9 The “LFQ” metric from the MaxQuant “protein group.txt” output was used to quantify proteins. Missing protein  
10 intensity values were replaced by a constant noise value determined independently for each sample as the lowest  
11 value of the total protein population. Only proteins identified in at least three samples in the same location (i.e.  
12 SC-Ad or BM-Ad) were considered as robustly detected and were used for statistical and bioinformatic analyses.  
13 Protein involved in lipid and glucose metabolism were selected using gene analytics software based on their  
14 involvement into the following pathways: Regulation of lipid metabolism; Insulin signaling-generic cascades;  
15 Lipoprotein metabolism; Adipogenesis; Regulation of lipid metabolism by Peroxisome proliferator-activated  
16 receptor alpha; Glucose / Energy Metabolism; Peroxisomal lipid metabolism; Calcium (Ca), cyclic adenosine  
17 monophosphate (cAMP) and Lipid Signaling; Nuclear Receptors in Lipid Metabolism and Toxicity; SREBF  
18 (Sterol Regulatory Element Binding Protein Gene) and miR33 in cholesterol and lipid homeostasis; Acyl chain  
19 remodeling of Phospho Ethanolamine (PE) ; Cholesterol and Sphingolipids transport / Distribution to the  
20 intracellular membrane compartments; Synthesis of substrates in N-glycan biosynthesis; Synthesis of Phosphatidyl  
21 Choline (PC); Metabolism of steroid hormones; Glycerophospholipid biosynthesis; Glucose metabolism; Fat  
22 digestion and absorption; Regulation of cholesterol biosynthesis by SREBP (Sterol Regulatory Element Binding  
23 Protein); cholesterol biosynthesis III (via desmosterol); Cholesterol and Sphingolipids transport / Transport from  
24 Golgi and ER to the apical membrane; Aldosterone synthesis and secretion; Citrate cycle (Tricarboxylic Acid  
25 (TCA) cycle); Adipocytokine signaling pathway; Sphingolipid metabolism; Fatty acid metabolism; Pyruvate  
26 metabolism; Arachidonic acid metabolism; Linoleic acid metabolism; Ceramide Pathway; Sphingolipid signaling  
27 pathway; sphingomyelin metabolism/ceramide salvage; Pentose phosphate pathway; Regulation of lipolysis in  
28 adipocytes; Mitochondrial Long Chain-Fatty Acid, Beta-Oxidation SuperPath; Fatty acid biosynthesis. Among the  
29 1948 proteins retrieved by the database, we robustly identified 612 proteins. The label free quantification (LFQ)  
30 intensity for each identified protein was log<sub>2</sub> transformed and used to perform the principal component analysis  
31 with R software (v3.5) and FactomineR package. The statistical analysis of differentially expressed proteins was  
32 performed with LIMMA package from Bioconductor using linear model followed by borrowing strength across  
33 protein with empirical bays methods with a design matrix build on two groups (BM-Ad and SC-Ad) (see  
34 Supplementary Table 1). The protein expression was considered significantly different if the p-value was lower  
35 than 0.05. Pathway enrichment analysis was performed with gene analytics software. The official gene symbol of  
36 the proteins significantly enriched or down-regulated was used as entry to determine the pathways enriched or  
37 downregulated respectively. The heatmaps and associated hierarchical clustering build on K-means methods were  
38 resolved with R and ggplot2 package.  
39  
40

## 1 ***In vitro* adipogenesis**

2 The pre-adipocyte 3T3 F442A obtained from ECACC (00070654) were grown and differentiated into adipocyte  
3 as previously described (Meulle et al, 2008). OP9 cell were obtained from ATCC (ATCC CRL-2749). OP9 cells  
4 were seeded at  $1 \times 10^5$  cell/well in 6-well plates for 2 days in MEM alpha supplemented with 20% fetal calf serum  
5 (FCS), 125 mg/mL streptomycin, 125 UI/mL penicillin. At 80% of confluence, media was replaced with similar  
6 media supplemented with 15% knock-out serum (invitrogen10828-028) for 5 days to induce adipogenic  
7 differentiation (Wolins et al, 2006). Human BM-MSC were isolated from bone marrow (obtained by sternal  
8 puncture) of healthy patients as previously described (Corre et al, 2007). BM-MSC (passage 2) were seeded at  
9  $3 \times 10^5$  cell/well in 6-well plates for 2 days in MEM alpha supplemented with 10% fetal calf serum (FCS),  
10 125mg/mL streptomycin, 125UI/mL penicillin. At 80% of confluence, media was replaced with StemMACS™  
11 AdipoDiff Media (Miltenyi 130-091-677) supplemented with 125mg/mL streptomycin, 125UI/mL penicillin to  
12 induce adipogenic differentiation for 28 days. Media was changed every 2 to 3 days and cells were grown in a  
13 humid atmosphere with 5% CO<sub>2</sub> at 37°C. TG content of cells before and at the end of adipogenic differentiation  
14 was performed as previously described (Dirat et al, 2011) using commercial kit (Sigma- F6428).

15

## 16 **Western blot**

17 Isolated adipocytes were washed 3 times with PBS and proteins were separated from lipids using MTBE extraction  
18 described above (proteomic analysis section). Five µg of proteins were reduced with modified Laemmli buffer for  
19 15 minutes at 65°C, loaded on 4-10% gradient SDS-PAGE gel (Biorad) and transferred to nitrocellulose  
20 membrane. Membranes were blocked with 5% skimmed milk in TBS (20mM Tris, 150mM NaCl) and incubated  
21 with appropriate primary antibodies (rabbit polyclonal antibody (pAb) anti ATGL, (1/:1000, ref: 2138, Cell  
22 Signaling Technology); rabbit pAb anti HSL (1:1000, ref: 4107, Cell Signaling Technology); rabbit pAb anti  
23 MAGL (1:1000, ref: sc134749, Santa Cruz Biotechnology); mouse monoclonal anti β-Actin (1:5000, clone: AC-  
24 15, Sigma Aldrich). The membranes were washed with TBS complemented with 0.1% Tween-20 and incubated  
25 with HRP conjugated secondary antibodies (1:5000, Santacruz Biotechnology). The immunoreactive protein bands  
26 were revealed by ECL prime Western blotting detection reagent (Amersham™) and detected using ChemiDoc™  
27 Imaging System (Biorad). Densitometry quantification was performed using image lab software (v5.2.1; Biorad).  
28 Signal intensity was normalized to β-Actin.

29

## 30 **Lipolysis assay**

31 Isolated adipocytes (50µl) were incubated with 450 µL KRBHA with or without isoprenaline  $10^{-6}$  mol. L<sup>-1</sup> (Sigma  
32 Aldrich) to evaluate stimulated and basal lipolysis respectively. After 2 h incubation at 37°C under gentle shaking,  
33 200 µL of incubation media was removed and kept to measure glycerol and FA release using commercial kits  
34 (Sigma- F6428 and Wako diagnostic NEFA-HR, respectively). Results were normalized to total lipid content  
35 quantified after Dole extraction. Briefly, isolated adipocytes were lysed by the addition of Dole's Reagent (40:10:1  
36 isopropanol : heptane : H<sub>2</sub>SO<sub>4</sub> 1N). Upper phase containing lipids was extracted again with heptane, evaporated  
37 under a nitrogen stream and dried lipids were weighted. For lipolysis experiment on adipocyte-differentiated cell  
38 lines (3T3 F442A and OP9) and human BM-MSC, cells were incubated for 3 hours and results were normalized  
39 to TG content. At the end of the incubation, cells were washed with PBS and resuspended in buffer containing  
40 10mM Tris HCL pH 7.5 and 1mM EDTA to quantify TG.

## 1 **Statistical analyses**

2 Statistical analyses were performed using Prism v4 (GraphPad Software). Comparison between two groups was  
3 performed using paired Student's t-test and multiple comparisons was performed by two-way ANOVA follow by  
4 Bonferroni post-test for n independent experiments. P-value was considered significant if lower than 0.05.

5

## 6 **Acknowledgements**

7 This work benefited from the assistance of Stephanie Balor and Vanessa Soldan from the Multiscale Electron  
8 Imaging platform (METi) of the Centre de Biologie Intégrative (Toulouse, France). Lipidomic analysis was  
9 performed at the Mass Spectrometry Facility of the Beth Israel Deaconess Medical Center (Boston, USA). This  
10 work by supported by the "Fondation de France (contract N° 171352) for running costs and a two-year post-  
11 doctoral fellowship for Camille Attané. David Estève received a post-doctoral fellowship from the Fondation pour  
12 La Recherche Médicale (SPF201809007124). This work also benefited from the Toulouse Réseau Imagerie (TRI)-  
13 RIO Optical Imaging Platform at the Institute of Pharmacology and Structural Biology (Genotoul, Toulouse,  
14 France) supported by grants from the Région Midi-Pyrénées (contrat de projets état-région), the Grand Toulouse  
15 community, the Association pour la Recherche sur le Cancer (Equipement 8505), the CNRS and the European  
16 Union through the Fonds Européen de Développement Régional program. We thank Life Science Editors for  
17 editorial assistance.

18

## 19 **Author contributions**

20 NR set up the conditions for harvesting BM-AT and SC-AT in close collaboration with CA and DE and supervised  
21 the samples collection. CA, DE, MM handled the AT samples and isolated adipocytes. DE performed the  
22 transmission electron microscopy (with the help of the METi platform) and the immunofluorescence experiments  
23 as well as image data analysis. CA performed sample preparation for proteomic and lipidomic studies, Western  
24 blot, cell culture (with the help of MM) and the lipolysis experiments. JC performed the isolation of human BM-  
25 MSC. KC performed the proteomics studies under the supervision of OS. DE and CA conducted analysis of  
26 lipidomic (with the help of PV) and proteomic data under the supervision of JI. CA, DE, PV, OS and CM analyzed  
27 the data. CA, DE and CM conceived the idea for this project and wrote the manuscript with significant inputs from  
28 all authors. CM supervised the study.

29

## 30 **Conflict of interest**

31 The authors declare they have no conflict of interest

32



## 1 **References**

- 2 Abella E, Feliu E, Granada I, Milla F, Oriol A, Ribera JM, Sanchez-Planell L, Berga LI, Reverter JC, Rozman C  
3 (2002) Bone marrow changes in anorexia nervosa are correlated with the amount of weight loss and not with other  
4 clinical findings. *American Journal of Clinical Pathology* **118**: 582-588  
5
- 6 Bartelt A, Heeren J (2014) Adipose tissue browning and metabolic health. *Nature Reviews Endocrinology* **10**: 24-  
7 36  
8
- 9 Bathija A, Davis S, Trubowitz S (1979) Bone marrow adipose tissue: response to acute starvation. *American*  
10 *Journal of Hematology* **6**: 191-198  
11
- 12 Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, Klibanski A, Miller KK  
13 (2010) Vertebral Bone Marrow Fat Is Positively Associated With Visceral Fat and Inversely Associated With IGF-  
14 1 in Obese Women. *Obesity* **19**: 49-53  
15
- 16 Breitkopf SB, Ricoult SJH, Yuan M, Xu Y, Peake DA, Manning BD, Asara JM (2017) A relative quantitative  
17 positive/negative ion switching method for untargeted lipidomics via high resolution LC-MS/MS from any  
18 biological source. *Metabolomics : Official Journal of the Metabolomic Society* **13**  
19
- 20 Cawthorn William P, Scheller Erica L, Learman Brian S, Parlee Sebastian D, Simon Becky R, Mori H, Ning X,  
21 Bree Adam J, Schell B, Broome David T, Soliman Sandra S, DelProposto Jenifer L, Lumeng Carey N, Mitra A,  
22 Pandit Sandeep V, Gallagher Katherine A, Miller Joshua D, Krishnan V, Hui Susanta K, Bredella Miriam A,  
23 Fazeli Pouneh K, Klibanski A, Horowitz Mark C, Rosen Clifford J, MacDougald Ormond A (2014) Bone Marrow  
24 Adipose Tissue Is an Endocrine Organ that Contributes to Increased Circulating Adiponectin during Caloric  
25 Restriction. *Cell Metabolism* **20**: 368-375  
26
- 27 Cawthorn WP, Scheller EL, Parlee SD, Pham HA, Learman BS, Redshaw CMH, Sulston RJ, Burr AA, Das AK,  
28 Simon BR, Mori H, Bree AJ, Schell B, Krishnan V, MacDougald OA (2016) Expansion of Bone Marrow Adipose  
29 Tissue During Caloric Restriction Is Associated With Increased Circulating Glucocorticoids and Not With  
30 Hypoleptinemia. *Endocrinology* **157**: 508-521  
31
- 32 Cinti S (2001) The adipose organ: morphological perspectives of adipose tissues. *The Proceedings of the Nutrition*  
33 *Society* **60**: 319-328  
34
- 35 Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B,  
36 Reme T, Bourin P (2007) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. *Leukemia*  
37 **21**: 1079-1088  
38
- 39 Devlin MJ, Cloutier AM, Thomas NA, Panus DA, Lotinun S, Pinz I, Baron R, Rosen CJ, Buxsein ML (2010)  
40 Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. *Journal of Bone and*  
41 *Mineral Research* **25**: 2078-2088  
42
- 43 Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, Huttemann M, Podgorski I (2016) Bone marrow  
44 adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1alpha activation. *Oncotarget*  
45 **7**: 64854-64877  
46
- 47 Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S,  
48 Garrido I, Escourrou G, Valet P, Muller C (2011) Cancer-associated adipocytes exhibit an activated phenotype  
49 and contribute to breast cancer invasion. *Cancer Research* **71**: 2455-2465  
50
- 51 Doucette CR, Horowitz MC, Berry R, MacDougald OA, Anunciado-Koza R, Koza RA, Rosen CJ (2015) A High  
52 Fat Diet Increases Bone Marrow Adipose Tissue (MAT) But Does Not Alter Trabecular or Cortical Bone Mass in  
53 C57BL/6J Mice. *Journal of Cellular Physiology* **230**: 2032-2037  
54
- 55 Fasshauer M, Blüher M (2015) Adipokines in health and disease. *Trends in Pharmacological Sciences* **36**: 461-  
56 470  
57
- 58 Ghali O, Al Rassy N, Hardouin P, Chauveau C (2016) Increased Bone Marrow Adiposity in a Context of Energy  
59 Deficit: The Tip of the Iceberg? *Frontiers in Endocrinology* **7**

- 1  
2 Giordano A, Smorlesi A, Frontini A, Barbatelli G, Cinti S (2014) White, brown and pink adipocytes: the  
3 extraordinary plasticity of the adipose organ. *European journal of Endocrinology* **170**: R159-171  
4  
5 Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I (2015) Marrow adipocyte-derived CXCL1 and  
6 CXCL2 contribute to osteolysis in metastatic prostate cancer. *Clinical & Experimental Metastasis* **32**: 353-368  
7  
8 Herroon MK, Rajagurubandara E, Hardaway AL, Powell K, Turchick A, Feldmann D, Podgorski I (2013) Bone  
9 marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. *Oncotarget* **4**: 2108-2123  
10  
11 Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G (2010) EANM Dosimetry Committee guidelines for bone  
12 marrow and whole-body dosimetry. *European Journal of Nuclear Medicine and Molecular Imaging* **37**: 1238-  
13 1250  
14  
15 Hodson L, Skeaff CM, Fielding BA (2008) Fatty acid composition of adipose tissue and blood in humans and its  
16 use as a biomarker of dietary intake. *Progress in Lipid Research* **47**: 348-380  
17  
18 Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M (2001) Adipocyte tissue volume in  
19 bone marrow is increased with aging and in patients with osteoporosis. *Biogerontology* **2**: 165-171  
20  
21 Kim SH, Cho KW, Choi HS, Park SJ, Rhee Y, Jung HS, Lim SK (2009) The forkhead transcription factor Foxc2  
22 stimulates osteoblast differentiation. *Biochemical and Biophysical Research Communications* **386**: 532-536  
23  
24 Krings A, Rahman S, Huang S, Lu Y, Czernik PJ, Lecka-Czernik B (2012) Bone marrow fat has brown adipose  
25 tissue characteristics, which are attenuated with aging and diabetes. *Bone* **50**: 546-552  
26  
27 Lafontan M, Langin D (2009) Lipolysis and lipid mobilization in human adipose tissue. *Progress in Lipid Research*  
28 **48**: 275-297  
29  
30 Lee MJ, Fried SK (2014) Optimal protocol for the differentiation and metabolic analysis of human adipose stromal  
31 cells. *Methods in Enzymology* **538**: 49-65  
32  
33 Leitner BP, Huang S, Brychta RJ, Duckworth CJ, Baskin AS, McGehee S, Tal I, Dieckmann W, Gupta G, Kolodny  
34 GM, Pacak K, Herscovitch P, Cypess AM, Chen KY (2017) Mapping of human brown adipose tissue in lean and  
35 obese young men. *Proceedings of the National Academy of Sciences of the United States of America* **114**: 8649-  
36 8654  
37  
38 Litvinov DY, Savushkin EV, Dergunov AD (2018) Intracellular and Plasma Membrane Events in Cholesterol  
39 Transport and Homeostasis. *Journal of Lipids* **2018**: 3965054  
40  
41 Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orłowski RZ, Yang J (2015) Mature  
42 adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. *Oncotarget*  
43 **6**: 34329-34341  
44  
45 Mattiucci D, Maurizi G, Izzi V, Cenci L, Ciurlantini M, Mancini S, Mensà E, Pascarella R, Vivarelli M, Olivieri  
46 A, Leoni P, Poloni A (2018) Bone marrow adipocytes support hematopoietic stem cell survival. *Journal of Cellular*  
47 *Physiology* **233**: 1500-1511  
48  
49 Meulle A, Salles B, Daviaud D, Valet P, Muller C (2008) Positive regulation of DNA double strand break repair  
50 activity during differentiation of long life span cells: the example of adipogenesis. *PLoS One* **3**: e3345  
51  
52 Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ (2009) Bone-marrow adipocytes as negative  
53 regulators of the haematopoietic microenvironment. *Nature* **460**: 259-263  
54  
55 Nedergaard J, Bengtsson T, Cannon B (2007) Unexpected evidence for active brown adipose tissue in adult  
56 humans. *Am J Physiol Endocrinol Metab* **293**: E444-452  
57  
58 Ninomiya Y, Sugahara-Yamashita Y, Nakachi Y, Tokuzawa Y, Okazaki Y, Nishiyama M (2010) Development of  
59 a rapid culture method to induce adipocyte differentiation of human bone marrow-derived mesenchymal stem  
60 cells. *Biochemical and Biophysical Research Communications* **394**: 303-308

- 1  
2 Nishikata I, Nakahata S, Saito Y, Kaneda K, Ichihara E, Yamakawa N, Morishita K (2011) Sumoylation of MEL1S  
3 at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced  
4 myeloid differentiation. *Oncogene* **30**: 4194-4207  
5  
6 Prentice KJ, Saksi J, Hotamisligil GS (2019) Adipokine FABP4 integrates energy stores and counter regulatory  
7 metabolic responses. *Journal of Lipid Research*  
8  
9 Robles H, Park S, Joens MS, Fitzpatrick JAJ, Craft CS, Scheller EL (2019) Characterization of the bone marrow  
10 adipocyte niche with three-dimensional electron microscopy. *Bone* **118**: 89-98  
11  
12 Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J, Iwanaga T, Miyagawa  
13 M, Kameya T, Nakada K, Kawai Y, Tsujisaki M (2009) High incidence of metabolically active brown adipose  
14 tissue in healthy adult humans: effects of cold exposure and adiposity. *Diabetes* **58**: 1526-1531  
15  
16 Scheller EL, Cawthorn WP, Burr AA, Horowitz MC, MacDougald OA (2016) Marrow Adipose Tissue: Trimming  
17 the Fat. *Trends in Endocrinology and Metabolism* **27**: 392-403  
18  
19 Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding SY, Bredella MA,  
20 Fazeli PK, Khoury B, Jepsen KJ, Pilch PF, Klibanski A, Rosen CJ, MacDougald OA (2015) Region-specific  
21 variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. *Nature*  
22 *Communications* **6**: 7808  
23  
24 Scheller EL, Khandaker S, Learman BS, Cawthorn WP, Anderson LM, Pham HA, Robles H, Wang Z, Li Z, Parlee  
25 SD, Simon BR, Mori H, Bree AJ, Craft CS, MacDougald OA (2019) Bone marrow adipocytes resist lipolysis and  
26 remodeling in response to beta-adrenergic stimulation. *Bone* **118**: 32-41  
27  
28 Scheller EL, Rosen CJ (2014) What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal  
29 health. *Ann N Y Acad Sci* **1311**: 14-30  
30  
31 Schreibman PH, Dell RB (1975) Human adipocyte cholesterol. Concentration, localization, synthesis, and  
32 turnover. *The Journal of Clinical Investigation* **55**: 986-993  
33  
34 Scott MA, Nguyen VT, Levi B, James AW (2011) Current methods of adipogenic differentiation of mesenchymal  
35 stem cells. *Stem Cells and Development* **20**: 1793-1804  
36  
37 Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, Piddock RE, Fenech M, Zaitseva L,  
38 Abdul-Aziz A, Turner J, Watkins JA, Lawes M, Bowles KM, Rushworth SA (2017) Leukemic blasts program  
39 bone marrow adipocytes to generate a protumoral microenvironment. *Blood* **129**: 1320-1332  
40  
41 Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo V, Ishizawa J,  
42 Hail N, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, Arai H, Nagaoka I, Miida T, Hayashizaki Y,  
43 Konopleva M, Andreeff M (2017) Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK  
44 and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. *Cancer Research* **77**:  
45 1453-1464  
46  
47 Taschler U, Radner FP, Heier C, Schreiber R, Schweiger M, Schoiswohl G, Preiss-Landl K, Jaeger D, Reiter B,  
48 Koefeler HC, Wojciechowski J, Theussl C, Penninger JM, Lass A, Haemmerle G, Zechner R, Zimmermann R  
49 (2011) Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance.  
50 *The Journal of Biological Chemistry* **286**: 17467-17477  
51  
52 Tavassoli M (1974) Differential response of bone marrow and extramedullary adipose cells to starvation.  
53 *Experientia* **30**: 424-425  
54  
55 Wen PC, Mahinthichaichan P, Trebesch N, Jiang T, Zhao Z, Shinn E, Wang Y, Shekhar M, Kapoor K, Chan CK,  
56 Tajkhorshid E (2018) Microscopic view of lipids and their diverse biological functions. *Current Opinion in*  
57 *Structural Biology* **51**: 177-186  
58

- 1 Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Park C, Choi K, Bickel PE (2006) OP9 mouse stromal cells  
2 rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. *Journal of Lipid*  
3 *Research* **47**: 450-460  
4
- 5 Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen KA, Nuutila P, Schaart G,  
6 Huang K, Tu H, van Marken Lichtenbelt WD, Hoeks J, Enerback S, Schrauwen P, Spiegelman BM (2012) Beige  
7 adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell* **150**: 366-376  
8
- 9 Yeung DKW, Griffith JF, Antonio GE, Lee FKH, Woo J, Leung PC (2005) Osteoporosis is associated with  
10 increased marrow fat content and decreased marrow fat unsaturation: A proton MR spectroscopy study. *Journal*  
11 *of Magnetic Resonance Imaging* **22**: 279-285  
12
- 13 Zechner R (2015) FAT FLUX: enzymes, regulators, and pathophysiology of intracellular lipolysis. *EMBO*  
14 *Molecular Medicine* **7**: 359-362  
15
- 16 Zhao S, Mugabo Y, Ballentine G, Attane C, Iglesias J, Poursharifi P, Zhang D, Nguyen Thuy A, Erb H, Prentki  
17 R, Peyot M-L, Joly E, Tobin S, Fulton S, Brown JM, Madiraju SRM, Prentki M (2016)  $\alpha/\beta$ -Hydrolase Domain 6  
18 Deletion Induces Adipose Browning and Prevents Obesity and Type 2 Diabetes. *Cell Reports* **14**: 2872-2888  
19
- 20 Zhou BO, Yu H, Yue R, Zhao Z, Rios JJ, Naveiras O, Morrison SJ (2017) Bone marrow adipocytes promote the  
21 regeneration of stem cells and haematopoiesis by secreting SCF. *Nature Cell Biology* **19**: 891-903  
22
- 23 Zingaretti MC, Crosta F, Vitali A, Guerrieri M, Frontini A, Cannon B, Nedergaard J, Cinti S (2009) The presence  
24 of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown  
25 adipose tissue. *FASEB J* **23**: 3113-3120  
26
- 27 Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV (2018) Anatomical, Physiological, and Functional  
28 Diversity of Adipose Tissue. *Cell Metabolism* **27**: 68-83  
29  
30  
31  
32  
33  
34  
35

## 1 **Figure legends**

2

### 3 **Fig 1: SC-Ad and BM-Ad exhibit similar morphological properties.**

4 **A.** Scheme of the experimental protocol designed to obtain paired human primary bone marrow (BM-Ad) and  
5 subcutaneous adipocytes (SC-Ad). Paired bone marrow (BM-AT) and subcutaneous adipose tissues (SC-AT) were  
6 harvested from patients undergoing hip replacement surgery. BM-AT, that share the same macroscopic aspects  
7 compared to SC-AT, was isolated from the red bone marrow containing hematopoietic cells. After enzymatic  
8 digestion, floating cells were rinsed and collected for subsequent experiments.

9 **B.** Whole mount SC-AT and BM-AT were stained with Bodipy 493/503 (neutral lipids, green), Phalloidin (F-  
10 Actin, red) and TOPRO-3 (nucleus, blue). Z stack images were taken using confocal microscope with 10X  
11 objective (n=3). Representative maximum intensity projection is shown. Orange arrowheads show vessels. White  
12 arrowheads show stromal cells. Scale bar, 100 $\mu$ m.

13 **C.** Transmission electron microscopy images of SC-AT and BM-AT. N: Nucleus, LD: Lipid Droplet, C:  
14 cytoplasm. Scale bar, 0.5 $\mu$ m.

15 **D.** Primary SC-Ad and BM-Ad were isolated and stained with Bodipy 493/503 (neutral lipids, green), phalloidin  
16 (F-actin, red) and TOPRO3 (nucleus, blue). Z stack images were taken using confocal microscope with 40X  
17 objective (n=3). Representative maximum intensity projection is shown. Scale bar, 50 $\mu$ m.

18

### 19 **Fig 2: Detailed lipid species analysis of BM-Ad shows increase free cholesterol and MG contents compared** 20 **to SC-Ad.**

21 **A.** Total lipid content in SC-AT and BM-AT (left, n=7) and in SC-Ad and BM-Ad (right, n=17) were extracted  
22 and weighted. The quantity of lipids was normalized to the quantity of tissue or the volume of adipocyte from  
23 which lipids were extracted. Histograms represent mean  $\pm$  SEM. ns stands for non-significant according to paired  
24 t test.

25 **B.** Pie chart of the relative abundance of the detected lipid classes using large-scale LC-MS/MS approaches. The  
26 glycerolipids (GL) are shown in blue shades. TG: triacylglycerol, DG: diacylglycerol, MG: monoacylglycerol;  
27 Phospholipids (PL) are in green shades. PC: phosphatidylcholine, PE: Phosphatidylethanolamine, PG:  
28 phosphatidylglycerol, PI: Phosphatidylinositol, PS: Phosphatidylserine, LPC: Lysophosphatidylcholine, LPE:  
29 Lysophosphatidylethanolamine, Sphingolipids (SL) are in yellow shades. SM: Sphingomyeline, Cer: Ceramides,  
30 So: Sphingosine; and fatty acid esters (FAE) are in pink shades. WE: Wax Ester, AcCA: Acyl Carnitine.

31 **C.** Violin plot representing the log<sub>2</sub> fold change of the 15 lipid classes identified in BM-Ad compared to SC-Ad  
32 analyzed by LC-MS/MS (n= 4). The quantity of lipid classes were calculated as the sum of the different lipid  
33 species belonging to the same classes.

34 **D:** Free cholesterol contents were measured using an enzymatic assay on lipid extracted from BM-Ad and SC-Ad.  
35 The results were normalized to the quantity of total lipids. The histograms represent mean  $\pm$  SEM, \*\*\* p<0. 001  
36 according to paired t test (n= 11).

37

### 38 **Fig 3: Large-scale proteome analysis highlights differences in lipid metabolism between BM-Ad and SC-** 39 **Ad.**



1 **A.** Principal component analysis of BM-Ad (grey) and SC-Ad (black) based on the relative quantification of the  
2 abundance of the proteins involved in lipid and glucose metabolism identified in the LC-MS/MS dataset. The first  
3 two components and the percentage of variance for each component are shown. Ellipses show the 95% confidence  
4 interval to strengthen the clustering of the tissues according to their anatomical locations.  
5 **B.** Volcano plot of the 612 proteins involved in lipid and glucose metabolism identified and quantified using LC-  
6 MS/MS analysis. Sixty seven proteins are significantly ( $p < 0.05$ ) enriched in BM-Ad (red circles), whereas 68  
7 proteins are significantly ( $p < 0.05$ ) down-regulated (blue circle) and 477 are unmodified (open circle) in BM-Ad  
8 compared to SC-Ad according to linear model statistical analysis.  
9 **C.** Pathway enrichment analysis performed with gene analytics. The top pathways enriched in BM-Ad (red bars)  
10 and down-regulated (blue bars) are presented.  
11 **D.** Heatmap of the relative abundance of proteins differentially expressed in BM-Ad and SC-Ad belonging to the  
12 lipoprotein metabolism pathway. Dendrogram represents hierarchical clustering of the samples. Blue squares  
13 represent down regulated proteins and red squares enriched proteins.

14  
15 **Fig 4: Human native BM-Ad are devoid of lipolytic activity, a metabolic trait not recapitulated by primary**  
16 **BM-MSCs differentiated *in vitro*.**

17 **A.** Left panel: Western blot analyses of the three main enzymes involved in lipolysis on paired isolated SC-Ad  
18 (SC) and BM-Ad (M) from 3 independent donors.  $\beta$ -actin is shown as loading control. Right panel: relative  
19 quantifications of the band intensity normalized to the quantity of  $\beta$ -actin. The histograms represent mean  $\pm$  SEM.  
20 ns=not significant. \*\*  $p < 0.01$  according to paired Student's t-test.

21 **B.** Glycerol release was measured from isolated SC-Ad and BM-Ad as readout of complete lipolysis under basal  
22 condition (plain bar) or after stimulation with isoprenaline (hatched bar). The data are mean of 7 independent  
23 experiments and normalized to the quantity of the total lipids content. The histograms represent mean  $\pm$  SEM, ns,  
24 not significant; \*\*\* $p < 0.001$  according to two-way ANOVA followed by Bonferroni post-test.

25 **C.** Free fatty acids (FFA) release from isolated SC-Ad and BM-Ad as readout of lipolysis under basal condition  
26 (plain bar) or after stimulation with isoprenaline (hatched bar). Data are mean of 7 independent experiments and  
27 are normalized to the quantity of the total lipids content. The histograms represent mean  $\pm$  SEM, ns, not significant;  
28 \*\* $p < 0.01$  according to two-way ANOVA followed by Bonferroni post-test.

29 **D.** TG content was measured in cell lysates from 3T3F442A (3T3) and OP9 cell lines or human BM-MSC (MSC)  
30 before and after adipogenic differentiation (nd: non-differentiated, d: differentiated). Data are mean of at least 4  
31 independent experiments (4 independent donors were used for human BM-MSC) and were normalized to the  
32 quantity of the total protein content. The histograms represent mean  $\pm$  SEM, \* $p < 0.05$ ; \*\* $p < 0.01$  according to two-  
33 way ANOVA followed by Bonferroni post-test

34 **E.** Glycerol release from *in vitro* differentiated 3T3F442A (3T3) and OP9 cell lines or human BM-MSC (MSC)  
35 as readout of complete lipolysis under basal conditions (plain bar) or after stimulation with isoprenaline (hatched  
36 bar). The data are mean of 3 independent experiments (3 independent donors were used for human BM-MSC) and  
37 were normalized to the quantity of the total lipids content. The histograms represent mean  $\pm$  SEM, \*  $p < 0.05$ ;  
38 \*\* $p < 0.01$  according to two-way ANOVA followed by Bonferroni post-test.

39  
40  
41



## 1 **Expanded View Figure legends**

2

### 3 **Fig EV1: SC-Ad and BM-Ad exhibit similar morphology**

4 **A.** Whole mount SC-Ad and BM-Ad were stained with an antibody directed against perilipin 1 (PLIN1, green),  
5 phalloidin (F-Actin, red) and TOPRO-3 (nucleus, blue). Z stack images were taken using confocal microscope  
6 with 40X objective (n=3). Representative maximum intensity projection is shown. Orange arrowheads show  
7 vessels and white arrowheads show stromal cells. Scale bar=50 $\mu$ m.

8 **B.** Representative XY and YZ focal planes are shown to highlight the cohesive organization of the SC- and BM-  
9 Ad and the thin cytoplasm of adipocytes (blue arrowheads).

10

### 11 **Fig EV2: Unsupervised lipidomic analyses reveal that the variance between samples mainly occur through** 12 **inter-individual variability despite increased MG species in BM-Ad.**

13 **A.** Principal component analysis of BM-Ad (grey) and SC-Ad (black) based on the relative quantification of the  
14 lipid species identified in LC-MS/MS. The first two components and the percentage of variance for each  
15 component are shown.

16 **B.** Heatmap of the relative abundance of lipid species quantified in BM-Ad and SC-Ad. Dendrogram represents  
17 hierarchical clustering of samples. Blue squares represent down-regulated lipid species and red squares enriched  
18 lipid species.

19 **C.** Relative quantification of the main MG species by LC-MS/MS in paired isolated SC-Ad and BM-Ad (n= 4).  
20 Histograms represent mean  $\pm$  SEM, \* p<0.05 according to two way ANOVA followed by Bonferroni's post-test.

21

### 22 **Fig EV3. Large-scale analysis of the proteome reveals differences in lipid metabolism, but not adipokines,** 23 **between BM-Ad and SC-Ad.**

24 **A.** Scheme of the proteomic dataset analysis workflow. Extracted proteins from paired isolated SC- and BM-Ad  
25 were analyzed by LC-MS/MS. Among the 3787 proteins identified, 3259 were robustly identified in at least 3 of  
26 4 donors. We selected a set of 612 proteins involved in lipid and glucose metabolism using gene analytics software  
27 to perform the statistical and bioinformatics analyses. In this dataset, unsupervised multivariate analysis was  
28 performed and differentially expressed proteins were identified using a linear statistical model (LIMMA) allowing  
29 to identify 67 proteins enriched and 68 proteins downregulated in BM-Ad compared to SC-Ad. Pathway  
30 enrichment analyses were performed using gene analytics software that concatenates several databases to identify  
31 specific lipid pathways enriched and down regulated in BM-Ad. Hierarchical clustering analyses were then  
32 performed on these specific lipid pathways.

33 **B.** Heatmap of the relative abundance of adipokines expressed in BM-Ad and SC-Ad. Dendrogram represents  
34 hierarchical clustering of the samples. Blue squares represents down regulated proteins and red squares enriched  
35 proteins.

36 **C.** Heatmaps of the relative abundance of proteins differentially expressed in BM-Ad and SC-Ad belonging to the  
37 Cholesterol Biosynthesis I and Statin pathway. Dendrogram represents hierarchical clustering of the samples. Blue  
38 squares represent down regulated proteins and red squares enriched proteins.

1 **D.** Heatmap of the relative abundance of proteins differentially expressed in BM-Ad and SC-Ad belonging to the  
 2 arachidonic acid metabolism pathway. Dendrogram represents hierarchical clustering of the samples. Blue squares  
 3 represents down regulated proteins and red squares enriched proteins.

4 **E.** Heatmap of the relative abundance of proteins differentially expressed in BM-Ad and SC-Ad belonging to the  
 5 FA metabolism pathway. Dendrogram represents hierarchical clustering of the samples. Blue squares represent  
 6 down regulated proteins. Red squares enriched proteins.

7  
 8 **Supplementary Table 1:**

9 Protein expression involved in lipid and glucose metabolism were quantified by nano LC-MS/MS. The log<sub>2</sub>  
 10 transformed average intensities of label free quantification (LFQ) in BM-Ad and SC-Ad for each protein in the  
 11 dataset and the corresponding log<sub>2</sub> fold change and p-Value are presented.

| Gene Symbol | Average expression in BM-Ad (log <sub>2</sub> LFQ intensity) | Average expression in SC-Ad (log <sub>2</sub> LFQ intensity) | log <sub>2</sub> Fold change (BM-Ad / SC-Ad) | P.Value   |
|-------------|--|--|--|-----------|
| S100A4      | 21,510   | 28,158   | -6,647                                       | 7,512E-05 |
| PPP1R1B     | 19,924   | 24,015   | -4,091                                       | 1,321E-05 |
| CLPP        | 20,921   | 24,880   | -3,959                                       | 4,754E-03 |
| ALDH1A1     | 24,112   | 27,738   | -3,625                                       | 8,082E-02 |
| ALDOC       | 25,733   | 29,330   | -3,598                                       | 4,918E-05 |
| SORBS1      | 23,500   | 26,875   | -3,375                                       | 5,411E-03 |
| PEMT        | 19,394   | 22,593   | -3,199                                       | 6,775E-03 |
| PHGDH       | 24,128   | 27,283   | -3,155                                       | 2,538E-02 |
| VLDLR       | 20,088   | 23,180   | -3,092                                       | 6,984E-03 |
| CSNK1G1     | 19,433   | 22,478   | -3,044                                       | 1,903E-05 |
| EIF4B       | 21,238   | 24,183   | -2,945                                       | 1,053E-03 |
| PTPRF       | 22,233   | 25,150   | -2,917                                       | 2,989E-02 |
| SH3KBP1     | 24,630   | 27,425   | -2,795                                       | 2,680E-03 |
| S100A6      | 26,210   | 28,958   | -2,748                                       | 1,790E-03 |
| ACSS2       | 22,832   | 25,485   | -2,653                                       | 4,720E-02 |
| EIF4H       | 22,319   | 24,938   | -2,618                                       | 1,063E-02 |
| UAP1        | 21,296   | 23,913   | -2,617                                       | 1,852E-02 |
| PTGR2       | 21,648   | 24,170   | -2,522                                       | 8,235E-03 |
| TXN2        | 21,132   | 23,585   | -2,453                                       | 2,475E-02 |
| MGLL        | 29,233   | 31,678   | -2,445                                       | 2,382E-04 |
| RAB9A       | 23,678   | 25,995   | -2,318                                       | 1,546E-03 |
| MAP2K2      | 21,165   | 23,458   | -2,292                                       | 9,283E-03 |
| ME3         | 22,294   | 24,573   | -2,279                                       | 1,045E-01 |
| SYNJ1       | 20,786   | 23,012   | -2,226                                       | 1,832E-01 |
| ACAD11      | 22,650   | 24,873   | -2,223                                       | 8,743E-02 |
| PLIN3       | 25,140   | 27,360   | -2,220                                       | 5,936E-02 |
| ACBD5       | 21,051   | 23,270   | -2,219                                       | 6,033E-02 |
| ACOT2       | 22,473   | 24,650   | -2,177                                       | 1,240E-01 |

|         |        |        |        |           |
|---------|--------|--------|--------|-----------|
| EXOC7   | 20,732 | 22,880 | -2,148 | 2,903E-02 |
| ADH1C   | 27,700 | 29,848 | -2,148 | 4,060E-02 |
| S100B   | 24,340 | 26,405 | -2,065 | 1,691E-02 |
| BDH1    | 21,644 | 23,685 | -2,041 | 4,369E-02 |
| ENPP1   | 24,585 | 26,575 | -1,990 | 3,336E-02 |
| MDH1    | 29,085 | 31,038 | -1,953 | 4,880E-03 |
| AKR1C2  | 28,260 | 30,180 | -1,920 | 1,803E-03 |
| COPZ2   | 21,636 | 23,480 | -1,844 | 2,309E-02 |
| ACADSB  | 24,280 | 26,115 | -1,835 | 1,092E-02 |
| GCDH    | 23,505 | 25,298 | -1,793 | 7,491E-02 |
| EPHX2   | 20,757 | 22,510 | -1,753 | 5,034E-02 |
| NQO1    | 28,498 | 30,248 | -1,750 | 1,928E-02 |
| PTGIS   | 21,603 | 23,333 | -1,729 | 1,778E-01 |
| PIK3R1  | 20,423 | 22,140 | -1,717 | 2,594E-02 |
| MRAS    | 25,950 | 27,653 | -1,703 | 3,280E-03 |
| AKAP1   | 21,940 | 23,623 | -1,683 | 1,381E-02 |
| MCEE    | 22,652 | 24,313 | -1,661 | 8,804E-02 |
| TOMM20  | 21,184 | 22,798 | -1,614 | 3,009E-02 |
| PLIN1   | 34,325 | 35,935 | -1,610 | 1,040E-02 |
| PCYT2   | 22,651 | 24,243 | -1,592 | 1,259E-01 |
| RELA    | 25,958 | 27,548 | -1,590 | 7,966E-03 |
| DDHD2   | 20,702 | 22,280 | -1,578 | 3,466E-02 |
| ACAT1   | 29,143 | 30,708 | -1,565 | 6,936E-03 |
| ANXA1   | 31,820 | 33,375 | -1,555 | 9,500E-03 |
| CBR3    | 23,495 | 25,018 | -1,523 | 5,170E-02 |
| GBE1    | 27,890 | 29,398 | -1,508 | 1,802E-02 |
| PRDX6   | 30,043 | 31,543 | -1,500 | 2,034E-02 |
| PYGB    | 26,510 | 27,990 | -1,480 | 6,462E-02 |
| TNFAIP8 | 21,773 | 23,248 | -1,475 | 5,419E-02 |
| AKR1C3  | 27,375 | 28,843 | -1,467 | 1,787E-02 |
| ARSA    | 21,528 | 22,990 | -1,463 | 3,140E-02 |
| GNPDA2  | 20,600 | 22,058 | -1,457 | 3,903E-02 |
| TKT     | 30,495 | 31,950 | -1,455 | 1,336E-02 |
| ACAD9   | 28,818 | 30,255 | -1,438 | 1,406E-01 |
| PDE3B   | 21,590 | 23,023 | -1,433 | 8,953E-02 |
| EIF2B3  | 19,956 | 21,368 | -1,411 | 1,522E-01 |
| CLTA    | 23,173 | 24,578 | -1,405 | 1,231E-01 |
| ANXA5   | 31,740 | 33,143 | -1,403 | 9,549E-03 |
| THRAP3  | 20,393 | 21,785 | -1,392 | 1,437E-02 |
| ME1     | 25,840 | 27,218 | -1,378 | 1,086E-01 |
| HK2     | 22,870 | 24,243 | -1,373 | 2,638E-01 |
| DECR2   | 23,328 | 24,683 | -1,355 | 1,035E-01 |
| CRAT    | 25,320 | 26,658 | -1,338 | 4,616E-02 |
| MPI     | 22,198 | 23,528 | -1,329 | 1,210E-01 |
| PRKCD   | 23,428 | 24,748 | -1,320 | 2,517E-02 |

|        |        |        |        |           |
|--------|--------|--------|--------|-----------|
| SAR1B  | 24,960 | 26,275 | -1,315 | 1,314E-02 |
| IDH3B  | 26,545 | 27,840 | -1,295 | 2,022E-02 |
| GRB2   | 23,590 | 24,885 | -1,295 | 3,304E-01 |
| EIF2S2 | 26,633 | 27,925 | -1,292 | 3,025E-02 |
| CRKL   | 22,267 | 23,553 | -1,286 | 2,396E-01 |
| ORMDL3 | 23,025 | 24,305 | -1,280 | 4,234E-02 |
| LDHA   | 29,758 | 31,033 | -1,275 | 5,285E-02 |
| VAPB   | 25,860 | 27,130 | -1,270 | 1,858E-02 |
| DBI    | 23,720 | 24,985 | -1,265 | 1,730E-01 |
| PDK1   | 21,443 | 22,700 | -1,257 | 2,004E-01 |
| GYS1   | 22,526 | 23,778 | -1,252 | 3,687E-01 |
| CNTRF  | 26,045 | 27,293 | -1,248 | 6,133E-02 |
| G6PD   | 27,770 | 27,668 | -1,247 | 2,904E-01 |
| PGM1   | 28,595 | 29,838 | -1,243 | 7,183E-02 |
| GPD1   | 31,363 | 32,605 | -1,242 | 5,701E-02 |
| HMOX2  | 24,040 | 25,280 | -1,240 | 1,002E-02 |
| ACYP2  | 21,996 | 23,233 | -1,237 | 1,044E-01 |
| HADH   | 30,430 | 31,653 | -1,223 | 2,698E-02 |
| DECR1  | 28,855 | 30,075 | -1,220 | 1,758E-02 |
| COPE   | 23,085 | 24,305 | -1,220 | 1,425E-01 |
| ALG11  | 21,844 | 23,055 | -1,211 | 2,749E-01 |
| FABP4  | 32,935 | 34,143 | -1,208 | 2,608E-02 |
| EIF4G2 | 22,870 | 24,078 | -1,208 | 1,477E-01 |
| SDHC   | 23,440 | 24,640 | -1,200 | 1,993E-01 |
| VAMP2  | 21,287 | 22,480 | -1,193 | 3,004E-01 |
| LIPE   | 30,383 | 31,570 | -1,188 | 1,674E-02 |
| NUDT14 | 20,362 | 21,544 | -1,183 | 2,165E-01 |
| LDHB   | 30,063 | 31,238 | -1,175 | 2,967E-02 |
| ELOVL5 | 23,850 | 25,008 | -1,158 | 3,533E-02 |
| ADH5   | 27,823 | 28,978 | -1,155 | 3,581E-02 |
| AGL    | 21,200 | 22,353 | -1,153 | 3,662E-01 |
| CALU   | 20,402 | 21,546 | -1,143 | 4,410E-01 |
| AGPAT3 | 23,693 | 24,803 | -1,110 | 1,558E-01 |
| ALDOA  | 30,130 | 31,230 | -1,100 | 4,271E-02 |
| ECHS1  | 29,710 | 30,810 | -1,100 | 4,715E-02 |
| PYGL   | 29,710 | 30,798 | -1,088 | 6,288E-02 |
| LMNA   | 32,478 | 32,663 | -1,085 | 7,168E-02 |
| MTAP   | 23,511 | 24,595 | -1,084 | 1,741E-01 |
| FITM2  | 23,398 | 24,478 | -1,080 | 5,798E-02 |
| PCBP2  | 25,328 | 25,410 | -1,079 | 2,997E-01 |
| STAT5A | 25,683 | 26,758 | -1,075 | 1,823E-01 |
| SHMT1  | 24,575 | 25,645 | -1,070 | 1,526E-01 |
| RRAS2  | 26,798 | 27,858 | -1,060 | 1,652E-02 |
| ENO1   | 31,025 | 32,075 | -1,050 | 7,524E-02 |
| UGP2   | 30,373 | 31,420 | -1,048 | 5,928E-02 |

|          |        |        |        |           |
|----------|--------|--------|--------|-----------|
| COL4A3BP | 21,720 | 22,760 | -1,040 | 1,652E-01 |
| JAK1     | 20,344 | 21,375 | -1,031 | 1,251E-01 |
| SCD      | 26,323 | 27,353 | -1,030 | 2,444E-01 |
| CAV1     | 27,958 | 27,965 | -1,025 | 6,888E-02 |
| ADH1B    | 31,945 | 32,968 | -1,022 | 6,785E-02 |
| GMPPB    | 20,315 | 21,326 | -1,011 | 4,475E-01 |
| AKT2     | 23,548 | 24,558 | -1,010 | 5,896E-02 |
| MYH7     | 22,304 | 23,298 | -0,994 | 6,288E-01 |
| PEA15    | 24,450 | 25,443 | -0,992 | 5,581E-02 |
| STAT5B   | 22,183 | 23,173 | -0,989 | 2,915E-01 |
| ACACA    | 24,598 | 25,578 | -0,980 | 4,458E-01 |
| MAPK3    | 24,765 | 25,743 | -0,978 | 1,467E-01 |
| PTPN11   | 24,473 | 25,448 | -0,975 | 1,107E-01 |
| TPT1     | 25,693 | 26,668 | -0,975 | 1,353E-01 |
| GRHPR    | 26,143 | 27,115 | -0,973 | 7,497E-02 |
| ECI2     | 23,563 | 24,523 | -0,960 | 6,278E-02 |
| RGN      | 21,100 | 22,058 | -0,958 | 2,620E-01 |
| ALDH2    | 31,980 | 32,935 | -0,955 | 8,121E-02 |
| PPP1CC   | 21,130 | 22,080 | -0,950 | 2,207E-01 |
| MECR     | 23,565 | 24,510 | -0,945 | 9,104E-02 |
| SLC25A10 | 24,358 | 25,300 | -0,942 | 8,690E-02 |
| OXCT1    | 28,070 | 29,008 | -0,938 | 6,051E-02 |
| LNPEP    | 26,973 | 27,903 | -0,930 | 1,339E-01 |
| SOD2     | 29,673 | 30,603 | -0,930 | 8,928E-02 |
| G0S2     | 21,776 | 22,705 | -0,929 | 2,520E-01 |
| HAGH     | 24,130 | 25,048 | -0,918 | 5,911E-02 |
| MUT      | 25,018 | 25,935 | -0,917 | 1,801E-01 |
| ANXA2    | 34,183 | 35,095 | -0,912 | 2,814E-02 |
| CRK      | 25,943 | 26,845 | -0,903 | 1,054E-01 |
| RAB5A    | 25,315 | 26,213 | -0,897 | 4,840E-02 |
| ACO1     | 29,453 | 30,335 | -0,883 | 1,360E-01 |
| ACAA1    | 25,528 | 26,403 | -0,875 | 7,343E-02 |
| IDH3A    | 26,998 | 27,873 | -0,875 | 7,145E-02 |
| GAPDH    | 30,563 | 31,435 | -0,873 | 5,790E-02 |
| CAMK1    | 22,318 | 23,185 | -0,868 | 1,827E-01 |
| RHOA     | 27,368 | 28,233 | -0,865 | 6,350E-02 |
| EIF4G1   | 24,173 | 25,035 | -0,863 | 2,585E-01 |
| EIF2S3   | 25,833 | 26,693 | -0,860 | 1,664E-01 |
| THRSP    | 20,503 | 21,363 | -0,859 | 1,567E-01 |
| EIF4E    | 22,545 | 23,403 | -0,858 | 3,308E-01 |
| NFKB1    | 21,205 | 22,063 | -0,858 | 2,634E-01 |
| PPIA     | 30,053 | 30,910 | -0,857 | 1,421E-01 |
| FASN     | 30,600 | 31,458 | -0,857 | 2,883E-01 |
| HADHB    | 30,380 | 31,233 | -0,852 | 5,646E-02 |
| PECR     | 27,355 | 28,208 | -0,852 | 6,796E-02 |

|         |        |        |        |           |
|---------|--------|--------|--------|-----------|
| MIF     | 23,883 | 24,728 | -0,845 | 2,918E-01 |
| TSPO    | 27,083 | 27,928 | -0,845 | 1,132E-01 |
| ACADS   | 28,128 | 28,960 | -0,833 | 7,945E-02 |
| GPI     | 25,183 | 26,010 | -0,827 | 1,741E-01 |
| ALDH1B1 | 25,643 | 26,465 | -0,823 | 1,673E-01 |
| RRAS    | 29,753 | 30,575 | -0,823 | 7,384E-02 |
| PPP2CA  | 24,073 | 24,893 | -0,820 | 2,076E-01 |
| ACOT1   | 29,290 | 30,103 | -0,813 | 1,188E-01 |
| PGD     | 29,210 | 30,023 | -0,813 | 1,356E-01 |
| PGK1    | 29,808 | 30,615 | -0,808 | 1,586E-01 |
| CS      | 30,343 | 31,145 | -0,802 | 1,349E-01 |
| MMAA    | 20,523 | 21,308 | -0,785 | 1,558E-01 |
| ALDH3A2 | 29,280 | 30,060 | -0,780 | 6,119E-02 |
| KRAS    | 25,825 | 26,600 | -0,775 | 1,303E-01 |
| CALM3   | 28,003 | 28,773 | -0,770 | 1,549E-01 |
| EIF2S1  | 25,945 | 26,710 | -0,765 | 1,644E-01 |
| LDHD    | 22,758 | 23,523 | -0,765 | 3,230E-01 |
| PCCA    | 26,190 | 26,955 | -0,765 | 3,906E-01 |
| GPD1L   | 22,261 | 23,021 | -0,760 | 6,414E-01 |
| EIF4A2  | 25,080 | 25,833 | -0,752 | 3,458E-01 |
| GPX4    | 27,275 | 28,020 | -0,745 | 1,683E-01 |
| PPP1CB  | 25,200 | 25,943 | -0,742 | 1,579E-01 |
| PDHX    | 25,648 | 26,388 | -0,740 | 1,683E-01 |
| LMF1    | 21,719 | 22,458 | -0,738 | 4,513E-01 |
| PPP2R2A | 24,848 | 25,585 | -0,738 | 3,263E-01 |
| SUCLG1  | 27,448 | 28,178 | -0,730 | 1,321E-01 |
| VAPA    | 26,855 | 27,568 | -0,712 | 9,879E-02 |
| ABCC1   | 19,646 | 20,353 | -0,707 | 9,581E-02 |
| FH      | 28,843 | 29,548 | -0,705 | 9,951E-02 |
| PRKAG1  | 23,095 | 23,800 | -0,705 | 4,227E-01 |
| CAT     | 31,095 | 31,798 | -0,703 | 1,287E-01 |
| SEC24A  | 19,860 | 20,562 | -0,701 | 2,690E-01 |
| LPIN1   | 21,059 | 21,758 | -0,699 | 2,660E-01 |
| NCL     | 27,858 | 28,545 | -0,688 | 2,326E-01 |
| CALU    | 28,695 | 29,378 | -0,682 | 1,644E-01 |
| PGLS    | 25,130 | 25,805 | -0,675 | 3,468E-01 |
| GLB1    | 21,619 | 22,285 | -0,666 | 3,993E-01 |
| PYGM    | 21,294 | 21,960 | -0,666 | 3,060E-01 |
| TALDO1  | 28,683 | 29,348 | -0,665 | 1,908E-01 |
| ACAA2   | 30,213 | 30,878 | -0,665 | 1,494E-01 |
| AKR1B1  | 24,163 | 24,825 | -0,662 | 6,971E-01 |
| BCAT2   | 24,810 | 25,470 | -0,660 | 2,511E-01 |
| CYCS    | 26,935 | 27,588 | -0,652 | 1,608E-01 |
| HMGCL   | 25,485 | 26,135 | -0,650 | 2,553E-01 |
| ACOT13  | 26,553 | 27,200 | -0,648 | 1,992E-01 |



|           |        |        |        |           |
|-----------|--------|--------|--------|-----------|
| CLIC4     | 24,415 | 25,060 | -0,645 | 5,769E-01 |
| CBR1      | 26,430 | 27,073 | -0,642 | 2,177E-01 |
| SUCLG2    | 28,205 | 28,843 | -0,637 | 1,526E-01 |
| C1QBP     | 26,195 | 26,825 | -0,630 | 1,668E-01 |
| PRKAR2B   | 28,915 | 29,545 | -0,630 | 2,234E-01 |
| AP2A1     | 25,335 | 25,958 | -0,622 | 6,271E-01 |
| DLST      | 29,028 | 29,648 | -0,620 | 1,610E-01 |
| PCCB      | 26,420 | 27,030 | -0,610 | 3,193E-01 |
| ILK       | 28,618 | 29,225 | -0,608 | 2,996E-01 |
| EGFR      | 24,615 | 25,223 | -0,608 | 2,175E-01 |
| AKT1      | 20,992 | 21,595 | -0,603 | 4,504E-01 |
| MDH2      | 29,795 | 30,395 | -0,600 | 1,701E-01 |
| DERA      | 22,394 | 22,983 | -0,589 | 5,086E-01 |
| GFPT1     | 23,475 | 24,060 | -0,585 | 5,159E-01 |
| NANS      | 22,890 | 23,468 | -0,578 | 5,148E-01 |
| GLTP      | 22,315 | 22,888 | -0,573 | 2,293E-01 |
| CTBP1     | 22,645 | 23,215 | -0,570 | 4,174E-01 |
| ATP2B4    | 28,193 | 28,760 | -0,568 | 3,037E-01 |
| FKBP4     | 21,975 | 22,535 | -0,560 | 6,602E-01 |
| EIF2AK2   | 21,151 | 21,710 | -0,559 | 3,927E-01 |
| TNFAIP8L2 | 20,415 | 20,968 | -0,553 | 3,841E-01 |
| DLD       | 29,223 | 29,775 | -0,553 | 2,426E-01 |
| MAPK14    | 21,572 | 22,123 | -0,551 | 4,852E-01 |
| PDHB      | 28,255 | 28,798 | -0,543 | 2,621E-01 |
| RAB7A     | 29,295 | 29,838 | -0,543 | 1,909E-01 |
| ABHD5     | 27,765 | 28,308 | -0,543 | 2,076E-01 |
| SUCLA2    | 27,880 | 28,408 | -0,527 | 2,437E-01 |
| RAB14     | 29,135 | 29,658 | -0,523 | 3,036E-01 |
| CD36      | 33,253 | 33,753 | -0,500 | 3,204E-01 |
| CIDEC     | 21,030 | 21,530 | -0,500 | 3,684E-01 |
| IDH3G     | 25,705 | 26,203 | -0,498 | 2,559E-01 |
| AGPAT2    | 26,430 | 26,928 | -0,497 | 3,141E-01 |
| RAP1B     | 25,225 | 25,718 | -0,493 | 2,454E-01 |
| GMPPA     | 22,403 | 22,895 | -0,492 | 4,502E-01 |
| ACACB     | 27,430 | 27,920 | -0,490 | 5,297E-01 |
| PGAM1     | 28,978 | 29,465 | -0,488 | 3,592E-01 |
| GNA12     | 21,925 | 22,413 | -0,487 | 3,618E-01 |
| BCL2      | 24,588 | 25,068 | -0,480 | 3,976E-01 |
| GLUD1     | 29,300 | 29,780 | -0,480 | 2,506E-01 |
| PPP3CB    | 23,345 | 23,813 | -0,467 | 4,656E-01 |
| ALDH9A1   | 28,690 | 29,150 | -0,460 | 4,400E-01 |
| LTA4H     | 24,930 | 25,388 | -0,458 | 6,721E-01 |
| NSDHL     | 24,625 | 25,083 | -0,457 | 3,236E-01 |
| MPC2      | 26,690 | 27,145 | -0,455 | 3,426E-01 |
| CSNK2A2   | 24,240 | 24,693 | -0,453 | 3,498E-01 |

|          |        |        |        |           |
|----------|--------|--------|--------|-----------|
| PAFAH1B1 | 26,225 | 26,668 | -0,442 | 3,707E-01 |
| ALG5     | 24,298 | 24,740 | -0,442 | 2,392E-01 |
| RPS6     | 24,880 | 25,318 | -0,438 | 2,872E-01 |
| PAFAH1B2 | 24,738 | 25,165 | -0,427 | 4,904E-01 |
| PPID     | 20,817 | 21,243 | -0,425 | 3,819E-01 |
| SORT1    | 25,568 | 25,988 | -0,420 | 3,812E-01 |
| RAP1A    | 29,748 | 30,163 | -0,415 | 3,081E-01 |
| CTSD     | 29,870 | 30,270 | -0,400 | 3,224E-01 |
| SLC27A4  | 21,114 | 21,505 | -0,391 | 5,333E-01 |
| RHEB     | 24,123 | 24,513 | -0,390 | 3,684E-01 |
| LONP1    | 26,935 | 27,320 | -0,385 | 4,389E-01 |
| CTSA     | 23,572 | 23,955 | -0,383 | 6,431E-01 |
| ACADL    | 23,235 | 23,618 | -0,383 | 8,034E-01 |
| ACOX2    | 21,435 | 21,815 | -0,380 | 5,367E-01 |
| HSD11B1  | 23,778 | 24,155 | -0,378 | 5,095E-01 |
| OGDH     | 28,125 | 28,498 | -0,372 | 6,288E-01 |
| TPI1     | 29,525 | 29,893 | -0,368 | 5,097E-01 |
| TXNRD1   | 22,601 | 22,968 | -0,367 | 7,535E-01 |
| SRC      | 20,872 | 21,230 | -0,358 | 6,435E-01 |
| RHOT2    | 21,113 | 21,462 | -0,349 | 6,649E-01 |
| HADHA    | 30,450 | 30,795 | -0,345 | 5,498E-01 |
| PCYT1A   | 25,275 | 25,620 | -0,345 | 4,611E-01 |
| AHCYL1   | 24,998 | 25,338 | -0,340 | 5,631E-01 |
| HDLBP    | 23,980 | 24,320 | -0,340 | 6,089E-01 |
| NDUFAB1  | 25,295 | 25,635 | -0,340 | 5,419E-01 |
| LRPAP1   | 27,390 | 27,720 | -0,330 | 5,653E-01 |
| ORMDL2   | 24,585 | 24,915 | -0,330 | 4,546E-01 |
| ACSL1    | 31,823 | 32,150 | -0,327 | 5,661E-01 |
| PPP2R5A  | 24,455 | 24,780 | -0,325 | 4,577E-01 |
| PLA2G4A  | 22,945 | 23,265 | -0,320 | 7,038E-01 |
| ARCNI    | 25,655 | 25,973 | -0,317 | 5,261E-01 |
| GPX1     | 27,760 | 28,073 | -0,313 | 6,313E-01 |
| PPP2R1A  | 26,995 | 27,305 | -0,310 | 6,006E-01 |
| ACADVL   | 30,198 | 30,503 | -0,305 | 4,925E-01 |
| GLO1     | 25,355 | 25,660 | -0,305 | 6,636E-01 |
| AGK      | 23,355 | 23,658 | -0,302 | 6,816E-01 |
| PDHA1    | 28,103 | 28,393 | -0,290 | 5,719E-01 |
| SLC25A1  | 28,795 | 29,083 | -0,288 | 5,751E-01 |
| ACOT9    | 26,268 | 26,555 | -0,287 | 5,447E-01 |
| RAC1     | 21,598 | 21,876 | -0,278 | 8,000E-01 |
| ACSF2    | 26,685 | 26,963 | -0,278 | 7,720E-01 |
| ARF1     | 28,873 | 29,143 | -0,270 | 6,100E-01 |
| ACOX1    | 26,630 | 26,893 | -0,262 | 4,995E-01 |
| MBNL1    | 21,482 | 21,740 | -0,258 | 5,905E-01 |
| ACADM    | 28,645 | 28,903 | -0,258 | 6,378E-01 |

|         |        |        |        |           |
|---------|--------|--------|--------|-----------|
| CAB39   | 24,205 | 24,460 | -0,255 | 6,102E-01 |
| DMGDH   | 21,395 | 21,650 | -0,255 | 6,445E-01 |
| PPP2R5D | 22,313 | 22,563 | -0,250 | 6,735E-01 |
| PRDX1   | 29,515 | 29,765 | -0,250 | 6,517E-01 |
| ECI1    | 26,585 | 26,830 | -0,245 | 6,288E-01 |
| PRDX2   | 29,950 | 30,183 | -0,232 | 6,284E-01 |
| ALDH7A1 | 27,715 | 27,943 | -0,228 | 5,909E-01 |
| PRKAR2A | 27,025 | 27,253 | -0,228 | 6,446E-01 |
| TXNRD2  | 22,968 | 23,195 | -0,228 | 7,202E-01 |
| CBR4    | 22,803 | 23,030 | -0,227 | 6,718E-01 |
| MAP2K1  | 26,143 | 26,365 | -0,222 | 6,870E-01 |
| PRPS1   | 23,850 | 24,070 | -0,220 | 6,957E-01 |
| FABP5   | 28,043 | 28,260 | -0,217 | 7,938E-01 |
| PRKACB  | 25,698 | 25,913 | -0,215 | 6,845E-01 |
| PTGES2  | 26,315 | 26,530 | -0,215 | 6,258E-01 |
| SIRT3   | 22,273 | 22,485 | -0,212 | 6,180E-01 |
| RPS27A  | 30,510 | 30,723 | -0,212 | 6,403E-01 |
| CPNE1   | 22,830 | 23,035 | -0,205 | 8,130E-01 |
| EIF4A1  | 28,038 | 28,240 | -0,202 | 7,332E-01 |
| ACOX3   | 20,660 | 20,855 | -0,195 | 7,095E-01 |
| AKR1A1  | 26,888 | 27,080 | -0,193 | 7,680E-01 |
| OPA1    | 26,870 | 27,063 | -0,193 | 7,149E-01 |
| SDHA    | 28,620 | 28,808 | -0,188 | 7,559E-01 |
| EHHADH  | 25,390 | 25,578 | -0,188 | 7,765E-01 |
| LMNA    | 26,265 | 27,350 | -0,185 | 6,737E-01 |
| HSD17B8 | 23,960 | 24,143 | -0,183 | 7,032E-01 |
| SUMF1   | 22,393 | 22,573 | -0,180 | 7,087E-01 |
| SLC2A4  | 24,963 | 25,143 | -0,180 | 6,969E-01 |
| EIF2B4  | 20,996 | 21,172 | -0,176 | 7,822E-01 |
| MAPK10  | 20,077 | 20,248 | -0,170 | 8,462E-01 |
| SDHB    | 27,208 | 27,365 | -0,157 | 7,565E-01 |
| COPZ1   | 23,603 | 23,753 | -0,150 | 7,910E-01 |
| STAT6   | 22,450 | 22,600 | -0,150 | 8,634E-01 |
| DLAT    | 28,483 | 28,630 | -0,148 | 7,965E-01 |
| HSD17B4 | 28,750 | 28,888 | -0,137 | 7,051E-01 |
| PKM     | 29,508 | 29,640 | -0,133 | 8,448E-01 |
| ITGB1   | 31,088 | 31,208 | -0,120 | 8,006E-01 |
| PGRMC1  | 28,945 | 29,060 | -0,115 | 8,409E-01 |
| PTPN1   | 22,534 | 22,648 | -0,113 | 7,828E-01 |
| ACO2    | 29,810 | 29,920 | -0,110 | 8,446E-01 |
| KPNB1   | 26,980 | 27,090 | -0,110 | 8,399E-01 |
| MFN2    | 23,533 | 23,643 | -0,110 | 8,982E-01 |
| PTGES3  | 23,418 | 23,528 | -0,110 | 8,705E-01 |
| ABHD6   | 20,067 | 20,166 | -0,099 | 8,263E-01 |
| ASAHI   | 28,788 | 28,880 | -0,093 | 8,383E-01 |

|          |        |        |        |           |
|----------|--------|--------|--------|-----------|
| TM7SF2   | 24,763 | 24,855 | -0,093 | 8,803E-01 |
| FDPS     | 24,825 | 24,913 | -0,087 | 9,123E-01 |
| PCBP2    | 20,363 | 21,441 | -0,082 | 8,716E-01 |
| TBC1D4   | 19,569 | 19,650 | -0,081 | 9,150E-01 |
| PIK3C3   | 20,449 | 20,529 | -0,080 | 9,225E-01 |
| ACSS3    | 26,318 | 26,395 | -0,078 | 8,845E-01 |
| INPP5K   | 22,288 | 22,363 | -0,075 | 8,497E-01 |
| SEC23A   | 25,588 | 25,663 | -0,075 | 9,066E-01 |
| CES1     | 33,438 | 33,500 | -0,062 | 9,284E-01 |
| TXN      | 26,313 | 26,373 | -0,060 | 9,126E-01 |
| SCP2     | 27,105 | 27,165 | -0,060 | 8,954E-01 |
| PMVK     | 21,574 | 21,634 | -0,059 | 9,446E-01 |
| GNAH1    | 27,903 | 27,953 | -0,050 | 9,270E-01 |
| VDAC1    | 30,060 | 30,105 | -0,045 | 9,123E-01 |
| STAT3    | 25,490 | 25,535 | -0,045 | 9,584E-01 |
| ADIPOQ   | 26,768 | 26,805 | -0,038 | 9,395E-01 |
| ROCK1    | 21,362 | 21,395 | -0,033 | 9,768E-01 |
| DGAT1    | 25,108 | 25,140 | -0,032 | 9,518E-01 |
| MPC1     | 24,775 | 24,798 | -0,023 | 9,599E-01 |
| S100A1   | 21,333 | 21,353 | -0,021 | 9,871E-01 |
| PON2     | 27,218 | 27,233 | -0,015 | 9,747E-01 |
| CAV1     | 33,368 | 34,393 | -0,008 | 9,938E-01 |
| TPM1     | 23,975 | 23,980 | -0,005 | 9,921E-01 |
| NCOA2    | 23,270 | 23,270 | 0,000  | 1,000E+00 |
| AP2A2    | 25,518 | 25,515 | 0,003  | 9,979E-01 |
| SLC25A11 | 28,483 | 28,480 | 0,003  | 9,954E-01 |
| VAC14    | 23,808 | 23,798 | 0,010  | 9,874E-01 |
| PC       | 30,178 | 30,168 | 0,010  | 9,847E-01 |
| PLBD1    | 22,825 | 22,810 | 0,015  | 9,824E-01 |
| COPG1    | 24,720 | 24,700 | 0,020  | 9,788E-01 |
| AP2B1    | 26,913 | 26,868 | 0,045  | 9,329E-01 |
| RUFY1    | 21,838 | 21,780 | 0,058  | 9,355E-01 |
| PTPMT1   | 22,998 | 22,938 | 0,060  | 9,036E-01 |
| IL6ST    | 21,391 | 21,321 | 0,070  | 9,235E-01 |
| LDLRAP1  | 19,544 | 19,470 | 0,074  | 8,895E-01 |
| CPT2     | 26,068 | 25,993 | 0,075  | 8,980E-01 |
| SLC25A5  | 28,065 | 27,973 | 0,092  | 8,147E-01 |
| MAPK1    | 26,530 | 26,438 | 0,093  | 8,775E-01 |
| PNPLA2   | 25,950 | 25,853 | 0,097  | 8,294E-01 |
| RAN      | 27,415 | 27,315 | 0,100  | 8,537E-01 |
| G6PD     | 23,448 | 24,695 | 0,103  | 8,594E-01 |
| HSPA5    | 31,928 | 31,818 | 0,110  | 8,099E-01 |
| PNPLA8   | 20,399 | 20,288 | 0,111  | 8,170E-01 |
| PCK1     | 25,128 | 25,015 | 0,113  | 8,337E-01 |
| MCU      | 24,275 | 24,160 | 0,115  | 8,109E-01 |

|          |        |        |       |           |
|----------|--------|--------|-------|-----------|
| IGF2R    | 22,825 | 22,703 | 0,123 | 7,513E-01 |
| PGM3     | 24,003 | 23,873 | 0,130 | 7,376E-01 |
| NPC2     | 22,299 | 22,165 | 0,134 | 8,323E-01 |
| COX4I1   | 30,003 | 29,858 | 0,145 | 7,614E-01 |
| VDAC2    | 29,335 | 29,183 | 0,153 | 7,197E-01 |
| SIRT5    | 21,632 | 21,463 | 0,169 | 6,768E-01 |
| ESYT2    | 28,400 | 28,228 | 0,172 | 7,127E-01 |
| HSD17B12 | 29,238 | 29,063 | 0,175 | 6,932E-01 |
| WFS1     | 25,410 | 25,230 | 0,180 | 7,388E-01 |
| ANXA7    | 27,615 | 27,425 | 0,190 | 6,878E-01 |
| ACAT2    | 23,025 | 22,827 | 0,198 | 8,506E-01 |
| PRKACA   | 29,903 | 29,703 | 0,200 | 6,638E-01 |
| DHCR7    | 24,095 | 23,890 | 0,205 | 6,676E-01 |
| CDC42    | 27,693 | 27,483 | 0,210 | 5,829E-01 |
| RHOQ     | 22,440 | 22,228 | 0,213 | 6,985E-01 |
| P4HB     | 32,263 | 32,050 | 0,213 | 6,262E-01 |
| CARM1    | 21,909 | 21,678 | 0,232 | 7,195E-01 |
| YAP1     | 23,905 | 23,663 | 0,242 | 6,723E-01 |
| H6PD     | 27,663 | 27,420 | 0,243 | 5,989E-01 |
| SLC9A3R2 | 22,978 | 22,733 | 0,245 | 5,944E-01 |
| PRKAA1   | 23,493 | 23,245 | 0,248 | 6,717E-01 |
| PHKB     | 20,700 | 20,450 | 0,249 | 7,253E-01 |
| LPGAT1   | 25,248 | 24,983 | 0,265 | 6,057E-01 |
| CPNE3    | 26,935 | 26,668 | 0,268 | 5,423E-01 |
| UGP2     | 22,192 | 21,924 | 0,268 | 8,071E-01 |
| IDH1     | 31,438 | 31,165 | 0,272 | 6,725E-01 |
| HK1      | 26,990 | 26,715 | 0,275 | 5,704E-01 |
| LEP      | 23,165 | 22,888 | 0,277 | 8,457E-01 |
| PRKAR1A  | 24,745 | 24,465 | 0,280 | 5,971E-01 |
| COPB2    | 25,823 | 25,540 | 0,282 | 7,023E-01 |
| OSBP     | 23,355 | 23,068 | 0,287 | 6,015E-01 |
| RAC3     | 22,150 | 21,858 | 0,292 | 7,934E-01 |
| EEF2     | 28,585 | 28,290 | 0,295 | 5,880E-01 |
| CSNK2B   | 24,240 | 23,943 | 0,297 | 4,811E-01 |
| BID      | 20,617 | 20,305 | 0,312 | 4,774E-01 |
| RAC1     | 28,920 | 28,608 | 0,313 | 4,289E-01 |
| PANK4    | 21,568 | 21,250 | 0,318 | 6,192E-01 |
| ACSF3    | 22,558 | 22,238 | 0,320 | 5,492E-01 |
| SLC27A1  | 25,828 | 25,503 | 0,325 | 6,558E-01 |
| ACTC1    | 30,865 | 30,528 | 0,337 | 5,789E-01 |
| PFKL     | 27,468 | 27,128 | 0,340 | 5,191E-01 |
| ROCK2    | 21,610 | 21,270 | 0,340 | 6,863E-01 |
| SUMF2    | 26,235 | 25,885 | 0,350 | 5,431E-01 |
| GNPDA1   | 24,165 | 23,800 | 0,365 | 7,674E-01 |
| GAA      | 24,515 | 24,145 | 0,370 | 5,027E-01 |

|          |        |        |       |           |
|----------|--------|--------|-------|-----------|
| CDIPT    | 25,733 | 25,360 | 0,372 | 3,732E-01 |
| CDS2     | 24,993 | 24,613 | 0,380 | 4,958E-01 |
| DEGS1    | 22,763 | 22,375 | 0,387 | 2,971E-01 |
| SERINC1  | 23,023 | 22,623 | 0,400 | 4,176E-01 |
| TRADD    | 21,042 | 20,632 | 0,409 | 6,571E-01 |
| EIF2B1   | 24,098 | 23,685 | 0,412 | 5,169E-01 |
| ALG12    | 21,448 | 21,036 | 0,413 | 6,181E-01 |
| MLYCD    | 24,013 | 23,595 | 0,417 | 5,866E-01 |
| APOA1    | 30,900 | 30,480 | 0,420 | 3,697E-01 |
| CERS4    | 20,815 | 20,395 | 0,420 | 2,896E-01 |
| ATP1B3   | 26,463 | 26,040 | 0,422 | 3,216E-01 |
| ZMPSTE24 | 25,538 | 25,110 | 0,428 | 3,707E-01 |
| ELOVL1   | 22,203 | 21,750 | 0,453 | 2,871E-01 |
| CSNK2A1  | 27,303 | 26,845 | 0,458 | 2,973E-01 |
| TPP2     | 20,866 | 20,403 | 0,463 | 5,714E-01 |
| GNAI3    | 26,690 | 26,225 | 0,465 | 3,420E-01 |
| AP2M1    | 27,298 | 26,830 | 0,467 | 2,527E-01 |
| OSBPL8   | 23,870 | 23,403 | 0,467 | 2,739E-01 |
| BDH2     | 24,268 | 23,800 | 0,467 | 5,762E-01 |
| HRAS     | 24,505 | 24,033 | 0,472 | 3,194E-01 |
| SLC25A12 | 24,808 | 24,335 | 0,472 | 3,057E-01 |
| COPB1    | 26,385 | 25,913 | 0,473 | 5,484E-01 |
| ACLY     | 23,675 | 23,200 | 0,475 | 6,793E-01 |
| SPTLC1   | 23,398 | 22,915 | 0,483 | 2,322E-01 |
| STAT1    | 25,950 | 25,458 | 0,493 | 4,316E-01 |
| PFKM     | 21,854 | 21,351 | 0,503 | 6,654E-01 |
| MB       | 20,354 | 19,840 | 0,514 | 3,349E-01 |
| ARSD     | 23,008 | 22,490 | 0,518 | 3,750E-01 |
| FDXR     | 23,438 | 22,918 | 0,520 | 2,431E-01 |
| ALG1     | 21,892 | 21,372 | 0,520 | 2,629E-01 |
| VDAC3    | 27,550 | 27,028 | 0,522 | 2,136E-01 |
| TECR     | 29,193 | 28,663 | 0,530 | 2,827E-01 |
| ACSL3    | 27,410 | 26,875 | 0,535 | 3,013E-01 |
| ABCD3    | 23,928 | 23,390 | 0,537 | 2,199E-01 |
| CALR     | 31,548 | 31,000 | 0,547 | 2,532E-01 |
| NR3C1    | 19,813 | 19,264 | 0,549 | 3,675E-01 |
| COPA     | 26,315 | 25,758 | 0,557 | 4,800E-01 |
| CACNA2D1 | 29,680 | 29,113 | 0,567 | 2,016E-01 |
| CLTC     | 29,645 | 29,073 | 0,572 | 3,323E-01 |
| CPT1A    | 22,385 | 21,800 | 0,585 | 5,497E-01 |
| MAP2K3   | 20,678 | 20,092 | 0,586 | 3,940E-01 |
| PGM2     | 22,935 | 22,338 | 0,597 | 5,736E-01 |
| DPM1     | 26,360 | 25,755 | 0,605 | 1,979E-01 |
| SLC2A1   | 22,392 | 21,785 | 0,607 | 6,349E-01 |
| AP2S1    | 25,680 | 25,073 | 0,608 | 1,618E-01 |



|          |        |        |       |           |
|----------|--------|--------|-------|-----------|
| SLC1A5   | 25,230 | 24,620 | 0,610 | 1,312E-01 |
| CANX     | 31,295 | 30,683 | 0,613 | 2,085E-01 |
| GNAI2    | 30,325 | 29,700 | 0,625 | 1,598E-01 |
| SACM1L   | 28,115 | 27,488 | 0,627 | 1,812E-01 |
| FBP1     | 23,678 | 23,048 | 0,630 | 3,150E-01 |
| PIP4K2A  | 23,038 | 22,403 | 0,635 | 1,606E-01 |
| ALG2     | 23,595 | 22,955 | 0,640 | 1,025E-01 |
| IDH2     | 29,333 | 28,690 | 0,643 | 1,983E-01 |
| ME2      | 25,603 | 24,935 | 0,667 | 3,972E-01 |
| SHMT2    | 24,360 | 23,690 | 0,670 | 3,134E-01 |
| LRP1     | 29,908 | 29,238 | 0,670 | 1,170E-01 |
| DPM3     | 24,243 | 23,570 | 0,672 | 1,376E-01 |
| GNA11    | 28,700 | 28,018 | 0,682 | 1,864E-01 |
| DOLPP1   | 22,315 | 21,623 | 0,693 | 2,389E-01 |
| GNAS     | 29,458 | 28,740 | 0,717 | 1,264E-01 |
| MICU1    | 20,311 | 19,590 | 0,721 | 2,059E-01 |
| TPM3     | 29,088 | 28,360 | 0,727 | 1,881E-01 |
| APOE     | 28,933 | 28,190 | 0,743 | 2,369E-01 |
| MPDU1    | 25,863 | 25,118 | 0,745 | 9,698E-02 |
| CAMK2D   | 24,433 | 23,688 | 0,745 | 5,675E-01 |
| PI4K2A   | 22,875 | 22,128 | 0,747 | 1,302E-01 |
| STIM1    | 24,935 | 24,178 | 0,758 | 1,838E-01 |
| ATP2A2   | 28,628 | 27,868 | 0,760 | 1,590E-01 |
| GM2A     | 22,595 | 21,833 | 0,762 | 1,586E-01 |
| SLC25A20 | 28,680 | 27,905 | 0,775 | 1,138E-01 |
| HACD2    | 27,880 | 27,098 | 0,783 | 2,516E-01 |
| CA2      | 25,323 | 24,518 | 0,805 | 2,055E-01 |
| NIPSNAP1 | 25,398 | 24,583 | 0,815 | 8,429E-02 |
| HACD3    | 26,843 | 26,020 | 0,822 | 6,652E-02 |
| LMAN2    | 28,353 | 27,530 | 0,823 | 4,972E-02 |
| HEXB     | 24,335 | 23,490 | 0,845 | 3,591E-01 |
| GOT2     | 26,125 | 25,280 | 0,845 | 5,826E-02 |
| SLC39A7  | 25,933 | 25,083 | 0,850 | 7,764E-02 |
| SLC25A13 | 25,613 | 24,755 | 0,857 | 9,936E-02 |
| PCK2     | 26,583 | 25,715 | 0,867 | 3,268E-01 |
| PRKACG   | 25,093 | 24,224 | 0,869 | 6,189E-01 |
| GSR      | 24,743 | 23,865 | 0,878 | 3,617E-01 |
| SLC27A3  | 23,958 | 23,063 | 0,895 | 1,105E-01 |
| HEXA     | 23,358 | 22,430 | 0,928 | 4,077E-01 |
| GGT1     | 24,045 | 23,108 | 0,938 | 7,498E-02 |
| GDE1     | 23,328 | 22,349 | 0,978 | 2,612E-01 |
| TPM1     | 24,883 | 23,900 | 0,982 | 2,579E-01 |
| NAGK     | 26,188 | 25,203 | 0,985 | 1,825E-01 |
| AGPAT1   | 21,845 | 20,845 | 1,000 | 2,648E-02 |
| PPT1     | 23,815 | 22,815 | 1,000 | 5,805E-02 |

|        |        |        |       |           |
|--------|--------|--------|-------|-----------|
| HBB    | 33,225 | 32,223 | 1,003 | 1,557E-01 |
| ABCD2  | 24,280 | 23,260 | 1,020 | 1,571E-01 |
| AGPS   | 25,013 | 23,978 | 1,035 | 5,669E-02 |
| PITPNB | 26,260 | 25,225 | 1,035 | 1,039E-01 |
| SEC24C | 22,814 | 21,740 | 1,074 | 3,334E-01 |
| RPTOR  | 22,558 | 21,454 | 1,104 | 3,708E-01 |
| GNAI3  | 27,445 | 26,340 | 1,105 | 1,835E-02 |
| GNAQ   | 27,898 | 26,770 | 1,128 | 4,301E-02 |
| SLC3A2 | 28,243 | 27,103 | 1,140 | 4,426E-02 |
| ADPGK  | 25,058 | 23,908 | 1,150 | 2,151E-02 |
| HBB    | 23,085 | 21,925 | 1,160 | 2,465E-01 |
| LMF2   | 24,653 | 23,488 | 1,165 | 1,924E-01 |
| ATP1A2 | 21,043 | 19,860 | 1,183 | 2,667E-01 |
| LPCAT3 | 25,613 | 24,420 | 1,193 | 1,589E-02 |
| FAF2   | 26,448 | 25,210 | 1,238 | 4,833E-02 |
| LPL    | 26,953 | 25,710 | 1,243 | 6,047E-02 |
| FLOT1  | 29,355 | 28,093 | 1,263 | 9,666E-03 |
| SGPL1  | 24,848 | 23,585 | 1,263 | 2,568E-02 |
| MARCKS | 25,815 | 24,530 | 1,285 | 3,148E-02 |
| GYG1   | 23,600 | 22,303 | 1,297 | 2,577E-01 |
| ALG9   | 21,539 | 20,230 | 1,308 | 2,007E-01 |
| TPM4   | 27,108 | 25,795 | 1,313 | 4,736E-02 |
| FTO    | 20,151 | 18,818 | 1,333 | 8,460E-02 |
| CETP   | 22,283 | 20,895 | 1,388 | 2,944E-01 |
| LBR    | 23,783 | 22,233 | 1,550 | 3,959E-03 |
| FHL2   | 21,466 | 19,898 | 1,568 | 6,794E-02 |
| FLOT2  | 28,985 | 27,415 | 1,570 | 1,921E-03 |
| GPAM   | 29,103 | 27,513 | 1,590 | 1,747E-02 |
| FTH1   | 30,675 | 29,048 | 1,627 | 2,952E-02 |
| CERS2  | 23,558 | 21,928 | 1,630 | 4,586E-03 |
| EBP    | 26,673 | 25,015 | 1,658 | 3,995E-03 |
| GPD2   | 27,785 | 26,045 | 1,740 | 4,302E-03 |
| FAAH   | 22,813 | 21,063 | 1,750 | 1,843E-02 |
| TSTA3  | 22,605 | 20,803 | 1,802 | 4,971E-02 |
| STS    | 24,490 | 22,675 | 1,815 | 6,994E-02 |
| MBOAT7 | 21,657 | 19,817 | 1,839 | 6,207E-02 |
| RENBP  | 21,822 | 19,949 | 1,873 | 5,151E-02 |
| CISD2  | 26,440 | 24,495 | 1,945 | 2,256E-03 |
| APOB   | 32,963 | 31,000 | 1,962 | 5,385E-02 |
| APOA2  | 28,030 | 26,020 | 2,010 | 7,845E-03 |
| PLD3   | 25,263 | 23,193 | 2,070 | 2,483E-03 |
| BAX    | 22,540 | 20,457 | 2,083 | 1,378E-02 |
| GSN    | 30,615 | 28,500 | 2,115 | 1,344E-03 |
| ATP1A1 | 25,875 | 23,717 | 2,158 | 2,182E-01 |
| LSS    | 30,078 | 27,870 | 2,208 | 4,347E-04 |

|          |        |        |       |           |
|----------|--------|--------|-------|-----------|
| PON1     | 26,048 | 23,833 | 2,215 | 1,494E-02 |
| HSD17B11 | 26,740 | 24,433 | 2,308 | 3,006E-03 |
| APOC2    | 22,375 | 20,002 | 2,373 | 8,739E-02 |
| APOC3    | 26,745 | 24,325 | 2,420 | 4,428E-02 |
| ALB      | 33,525 | 31,055 | 2,470 | 9,886E-04 |
| AGT      | 22,485 | 20,000 | 2,485 | 6,158E-03 |
| SLC44A2  | 25,845 | 23,323 | 2,523 | 1,477E-03 |
| ALDH3B1  | 24,705 | 22,160 | 2,545 | 3,735E-03 |
| CALML5   | 22,247 | 19,691 | 2,556 | 3,496E-02 |
| ALDH1A3  | 22,230 | 19,656 | 2,573 | 2,433E-02 |
| LIPA     | 23,090 | 20,432 | 2,658 | 2,828E-03 |
| MYL3     | 23,539 | 20,846 | 2,693 | 1,238E-01 |
| STAT2    | 24,208 | 21,466 | 2,741 | 1,416E-02 |
| ITPR1    | 24,040 | 21,073 | 2,967 | 1,057E-03 |
| CYP1B1   | 22,454 | 19,444 | 3,010 | 1,825E-02 |
| SERPINA5 | 21,955 | 18,943 | 3,012 | 2,390E-04 |
| PLTP     | 23,656 | 20,610 | 3,046 | 9,504E-02 |
| ARG1     | 24,455 | 21,233 | 3,223 | 4,346E-02 |
| UBB      | 29,808 | 26,523 | 3,285 | 5,891E-03 |
| A2M      | 29,603 | 26,253 | 3,350 | 1,408E-03 |
| APOC4    | 25,763 | 22,380 | 3,383 | 6,086E-02 |
| APOM     | 26,345 | 22,918 | 3,428 | 5,010E-03 |
| ALOX5AP  | 24,353 | 20,849 | 3,503 | 2,028E-03 |
| VTN      | 30,165 | 26,660 | 3,505 | 1,790E-03 |
| PLG      | 25,163 | 21,618 | 3,544 | 2,126E-02 |
| PTGS1    | 24,185 | 20,482 | 3,703 | 2,335E-04 |
| RAC2     | 23,092 | 19,358 | 3,733 | 3,912E-03 |
| ALOX5    | 22,758 | 18,994 | 3,764 | 7,134E-04 |
| HSD17B7  | 23,150 | 19,384 | 3,766 | 2,950E-05 |
| GMDS     | 22,397 | 18,631 | 3,766 | 2,509E-03 |
| CTNNA1   | 23,310 | 19,526 | 3,784 | 5,420E-03 |
| LEPR     | 26,410 | 22,589 | 3,821 | 4,565E-04 |
| TBXAS1   | 23,670 | 19,704 | 3,966 | 2,679E-04 |
| CIDEA    | 22,695 | 18,691 | 4,004 | 8,299E-04 |
| AHSG     | 25,720 | 21,503 | 4,217 | 2,558E-03 |
| FCER1G   | 24,295 | 20,024 | 4,271 | 1,277E-03 |
| TTR      | 26,263 | 21,823 | 4,439 | 1,271E-04 |
| TGM2     | 25,733 | 21,193 | 4,540 | 2,875E-04 |
| APOC1    | 26,755 | 22,194 | 4,561 | 6,490E-03 |
| NCEH1    | 25,235 | 20,393 | 4,842 | 1,341E-04 |
| APOH     | 28,385 | 23,403 | 4,983 | 2,548E-05 |
| GGT5     | 28,585 | 22,675 | 5,910 | 3,971E-05 |
| RAF1     | 26,733 | 20,811 | 5,922 | 4,107E-05 |
| CP       | 28,283 | 21,710 | 6,573 | 4,466E-05 |

**Fig 1**






Fig EV1

A



B



**Fig 2**








Fig EV2


A



B








C







**Fig EV3****A****B****Adipokines expression****C****Cholesterol biosynthesis and Statin Pathway****D****Arachidonic Acid Metabolism****E****Fatty Acid Metabolism**

**Fig 4**

